Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID: SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
NEWS
                Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
                CA/CAPLUS - Russian Agency for Patents and Trademarks
NEWS 3
        FEB 25
                 (ROSPATENT) added to list of core patent offices covered
NEWS
        FEB 28
                PATDPAFULL - New display fields provide for legal status
                data from INPADOC
NEWS
        FEB 28
                BABS - Current-awareness alerts (SDIs) available
NEWS
        FEB 28
                MEDLINE/LMEDLINE reloaded
NEWS
     7
        MAR 02 GBFULL: New full-text patent database on STN
NEWS 8 MAR 03 .REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22 PATDPASPC - New patent database available
```

NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 21:48:09 ON 03 APR 2005

=> file reg COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 21:48:18 ON 03 APR 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 APR 2005 HIGHEST RN 847818-85-3 DICTIONARY FILE UPDATES: 1 APR 2005 HIGHEST RN 847818-85-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=>

Uploading C:\Program Files\Stnexp\Queries\10723208.str

chain nodes :
11 12 13 16 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
7-16 8-11 11-12 11-18 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
7-16 11-18 12-13
exact bonds :
8-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

G1:H,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:CLASS 13:CLASS 16:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1STR

G1 H, O

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 21:48:41 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 336 TO ITERATE

100.0% PROCESSED 336 ITERATIONS 6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

5621 TO 7819

PROJECTED ANSWERS:

6 TO 266

L2

6 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 21:48:48 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 7444 TO ITERATE

100.0% PROCESSED 7444 ITERATIONS

108 ANSWERS

SEARCH TIME: 00.00.01

L3 108 SEA SSS FUL L1

Page 3

saeed

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 161.33 161.54

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 21:48:54 ON 03 APR 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Apr 2005 VOL 142 ISS 15 FILE LAST UPDATED: 1 Apr 2005 (20050401/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 L4 55 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 2004:769030 CAPLUS DOCUMENT NUMBER: 141:41067 111LE: ASYEMBET'S STATEMENT OF THE PROPERTY OF THE PROPERTY

TT

141:410687
Asymmetric synthesis of (R)-(+)-6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-hydroxyphenyl)hexanoic acid as a key intermediate for a neurodesenerative disease agent lkemoto, Tomomis Nagata, Toshiakis Yamano, Mitsuhisas Ito, Tatsuyas Mizuno, Yukior Tomimatsu, Kiminori Chemical Development Laboratories, Takeda Chemical Industries, Ltd., Yodogawa-ku, Osaka, 532-866, Japan Tetrahedron Letters (2004), 45(41), 7757-7760 COEN: TELEAY, ISSN: 0040-4039 Elsevier B.V. Journal English AUTHOR (S): CORPORATE SOURCE:

SOURCE:

PUBLI SHER: DOCUMENT TYPE: LANGUAGE: GI English

T

An asym. synthesis of (R)-(+)-6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-hydroxyphenyl) hexanoic acid (I) as a key intermediate for a neurodegenerative disease agent has been developed. A key reaction was an asym. hydrogenation of hindered acrylic acid II, catalyzed by the Rh-JOSIPHOS system in the presence of a base, to afford a chiral acid with very good enanticselectivity.
791096-78-19

791094-78-1P
RL: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of naphthyl(hydroxyphenyl)hexanoic acid via recrystn of chiral naphthyl(methoxymethyloxyphenyl)propanoic acid with brucine followed by reduction, olefination, hydrogenation, and deprotection)
791095-78-1 CAPIUS
2-Naphthalenepropanamide, N,1,4-trimethoxy-β-[4-(methoxymethoxy)phenyl]-N,3-dimethyl-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
11TLE:
1NVENTOR(S):
2004:467872 CAPLUS
141:38948
Preparation of piperazinedione derivatives for use in treating obesity
Conde-Frieboes, Kilian Waldemar, Ankersen, Michael, Sensfuss, Ulrich, Wulff, Birgitte Schjellerup;
Thogersen, Henning, Lustenberger, Philipp, Rudolf, Klausr Krist, Bernd, Mueller, Stephan, Stenkamp, Dirk, Schindler, Marcusy Weisland, Heiker Arndt, Kirsten
Novo Nordisk A/S, Den., Boehringer Ingelheim international G, m.b.H.
PCT Int. Appl., 196 pp.
COODEN: PIXXD2
Patent INFORMATION:
11

2004:467872 CAPLUS
Preparation of piperazinedione derivatives for use in treating charactering the preparation of piperazinedione derivatives for use in treating charactering the preparation of piperazinedione derivatives for use in treating charactering the preparation of piperazinedione derivatives for use in treating charactering the preparation of piperazinedione derivatives for use in treating observer.

Sensfuss, Ulrich, Wulff, Birgitte Schjellerup;
Thogersen, Henning, Lustenberger, Philipp, Rudolf, Klausr Krist, Bernd Hueller, Stephan, Stenkamp, Dirk, Schindler, Marcusy Weisland, Heiker Arndt, Kirsten
Novo Nordisk A/S, Den., Boehringer Ingelheim
International G, m.b.H.
PCT Int. Appl., 196 pp.
COODEN: PIXXD2
Patent Type:
PATENT INFORMATION:
PATENT INFORMATION:

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PAT	ENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D	ATE		
							-									-			
	WO	2004	0483	45		A2		2004	0610		WO 2	003-	DX79	7		2	0031	120	
	WO	2004	0483	45		A3		2004	0715										
		¥:	AE,	AG,	AL,	AM.	AT,	AU,	AZ,	BA.	BB.	BG.	BR.	BW.	BY.	BZ.	CA.	CH.	
									DK,										
									IL,										
									MA,										
									RO,										
									UG,										
		RW:							MZ,								AM.	AZ.	
									TM,										
									IE,										
			TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE.	SN,	TD.	TG
PRIOR	RITY	APP																	
OTHER	R SC	URCE	(5):			MAR	PAT	141:	3884										
GI																			

AB The invention relates to piperazinediones I (R1 = H or alk(en)(yn)yl; R2 = Page 5

saeed

ANSWER 1 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT:

THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 22

ANSWER 2 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
-(CH2)1-5-A, where A is an amino or guanidinyl group; R3 is -(CH2)0-2-E,
where E is (un)substituted cycloskyl, heterocyclyl, aryl or heteroaryl;
R4 --(CH2)0-2(CH3)0-2-G2, where G1 is (un)substituted alkyl, alkowy,
cycloskyl, cycloskowy, aryl or heteroaryl and G2 is cycloskyl, slowy,
cycloskyl, cycloskowy, aryl or heteroaryl and G2 is cycloskyl,
heterocyclyl, aryl or heteroaryl as well as any optical or geometric
isomer or tautomer forms or pharmaceutically-acceptable salts for use as
agonists of melanocortin receptors in the treatment of obesity. Thus,
compd. II was prepd. and assayed for effect on food intake in rats
(results shown graphically).
702691-47-2P.
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of piperaxinedione derivs. for treating obesity)
702691-47-2 CAPLUS
L-Alanine, N2-((1,1'-biphenyl)-4-ylmethyl)-N6-[(1,1dimethylethoxyl carbonyl)-L-lysyl-3-(1-methoxy-2-naphthalenyl)-, ethyl
ester (SCI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 2003:27631 CAPLUS DOCUMENT NUMBER: 139:190610 139:190610

GSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine

hallucinogens

hallucinogens Clare, Brian W. Department of Chemistry, The University of Western Australia, Crawley, 6009, Australia Journal of Computer-Aided Molecular Design (2002), 16(8/9), 611-633 CODEN: JCADEQ, 15SN: 0920-654X Kluwer Academic Publishers AUTHOR (S): CORPORATE SOURCE:

SOURCE:

PUBLISHER:

Aluwer Academic Publishers

GUMENT TYPE: Journal

GUMENT TYPE: Journal

GUMENT TYPE: Journal

GUMENT TYPE: Journal

English

A phys. model of electronic effects in the QSAR of benzens derivs.,

together with a regression technique for finding predictive equations, is

presented. The model is simple, based on the quantum theoretic

description of the benzens mol., and accounts for the variance in activity

of hallucinogenic phenylalkylamines as well as a classical description in

terms of electronic (atomic charge, orbital energy), hydrophobic (Hansch

s) and steric (substituent volume) terms. The new model involves the

energies of four x-like near frontier orbitals and the orientations of

their nodes. It is less affected by colinearity than the classical

approach. This model more than any other illustrates the essential wave

mech. nature of the interaction of a drug with its receptor, as the

x-like orbitals involved are standing waves of probability of finding

an electron in a given location in the field of the atomic nuclei, and have

no classical counterpert.

207740-21-4

RI. PAC (Pharmacological activities are DOCUMENT TYPE: LANGUAGE: AB A phys. m

RL: PAC (Pharmacological activity), PRP (Properties), BIOL (Biological

study)
(QSAR of benzene derivs. and comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens)
207740-21-4 CAZLUS
2-Naphthaleneethanamine, 1,4-dimethoxy- (9CI) (CA INDEX NAME)

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) derivs., are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intracocular pressure, as well as a method for the treatment of glaucoma, using compns. contg. one or more of the invention compds. In particular, compds. I are claimed (wherein R1, R2, R3 are independently chosen from H or an alkyl group, R4 is H or OR1, R5 is OCONRIR2, OCOR1, or OR7, R6 is H, OR7, CONRIR2, CH2OR7, CO2RIR2 (sic), NRIR2, with the proviso that both R5 and R6 are not H; X is at least one fused aryl group; A is chosen from H, an alkyl group, C(O)OR7, OR7, CR7, (C)ONRIR2, SC2NRIR2, halogen, or CF3; and R7 is H, (un) substituted alkyl group, C1-3 CORRIR2, C1-3 NRIR2, CO2H, or CO2(C1-3-alkyl1). Twelve synthetic examples are given. For instance, 1,4-dimethoxynaphthalene underwent a sequence of (1) formylation in the 2-position using MeOCHC12 and SnC14; (2) condensation of the resultant aldehyde with EtNO2 to give the corresponding 1-aryl-2-nitropropene; and (3) complete redn. of the unsatd. nitro function using LiAlH4, to give title compd. II, isolated as the KCl salt. This salt bound to rat cortical 5-HTZ receptors in vitro with an IC50 of 0.73 mM, vs. 0.941 nM for 5-HT itself. II.HCl also acted as a 5-HTZ agonist in a phosphoinositide turnover assay, with an EC50 of 239 nM and an efficacy (Emma) of 1184, vs. 469 nM and 1004 for 5-HT itself. 477904-65-7P, 2-(1-Methoxynaphthalen-2-yl)-1-methylethylamine hydrochloride
RL: PAC (Pharmacological activity), RCT (Reactant) SPN (Synthetic preparation); RACT (Reactant or reagent), USES (Uses) (drug candidate; preparation of novel naphthylaminopropane analogs with 5-HTZ receptor activity for use in the treatment of glaucoma) 477904-65-7 CAPLUS

2-Naphthaleneethanamine, 1-methoxy- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)

● HC1

Page 6

477904-62-4P, 2-(1,4-Dimethoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-63-5P, 2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)propan-1-ol hydrochloride 477904-64-6P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)propan-1-ol hydrochloride 477904-66-6P, 2-(4-Bromo-1-methoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-68-0P, 2-(1-Hydroxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-73-7P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-73-7P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-73-7P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-73-7P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)-1-methylethylamine hydrochloride 477904-73-7P, (1S, 2R)-2-Amino-1-(1,4-dimethoxynaphthalen-2-yl)-1-methylamine hydrochloride 477904-73-7P, (1S, 2R)-1-methylamine hydrochloride 47 Yl)propan-1-ol
RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU
(Therapeutic use), BIOL (Biological study), PREP (Preparation), USES

(drug candidate, preparation of novel naphthylaminopropane analogs with 5-HT2 receptor activity for use in the treatment of glaucoma)
RN 47894-62-4 CAPLUS

saeed

L4 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 2002:946090 CAPLUS DOCUMENT NUMBER: 138:24554

138:24554
Novel arylaminopropene analogs, particularly naphthylaminopropene derivatives, with 5-HT2 receptor activity, and their use for lowering intraocular pressure in the treatment of glaucoma Hellberg, Mark R., Namil, Abdelmoula Alcon, Inc., Switz.
PCT Int. Appl., 33 pp.
CODEN: PIXXD2
Patent

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: Patent English

FAMILY ACC. NUM. COUNT:

	PAT	ENT I	NO.			KIN	D	DATE			APPL	ICAT	ION :	NO.		D		
	WO	2002																
		w:						AU,										
								DK,										
			GΜ,	HR,	ΗU,	ID,	IL,	IN,	ıs,	J₽,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH.
			PL,	PT,	RO,	RU,	SD,	SE,	5G,	SI,	SK,	SL,	TJ,	TH,	TN.	TR,	TT.	TZ.
			UA,	UG,	US,	υz,	VN,	YU,	ZA,	211,	ZW,	AM,	AZ,	BY,	KG.	KZ.	MD.	RU.
				TM									-		-	-		
		RW:	GH.	GM.	KE.	Ls.	MW.	M2,	SD.	SL.	SZ.	TZ.	UG.	ZM.	ZW.	AT.	BR.	CH.
								FR,										
								CM,										
	CA	2447																
		1392																
								ES,										
								RO,						,	,	,	,	,
	BB	2002												۵		,	ດດວດ	630
		2004																
		2004															0031	
DDIA	171	APP	110, 110	T N TO		~1		2004	0010			001-						
PRIOR		AFF	LN.	INFO	• •							001-						
A-11127		NI DOE				MED		120.	2455		w U 2	002-	0210	042	,	• 2	0020	530
OINER	, 50	URCE	(5):			MAR	PAI	138:	44334	•								

New arylaminopropane analogs, and particularly naphthylaminopropane

ANSWER 4 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continue 2-Naphthaleneethanamine, 1,4-dimethoxy-c-methyl-, hydrochloride (9CI) (CA INDEX NAME) (Continued)

HC1

477904-63-5 CAPLUS 2-Naphthalenemethanol, α -(1-aminoethyl)-1,4-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)

● HC1

477904-64-6 CAPLUS 2-Naphthalenemethanol, $\alpha-\{\{1R\}-1-aminoethyl\}-1,4-dimethoxy-,hydrochloride, <math>\{as\}-\{9CI\}$ (CA INDEX NAME)

Absolute stereochemistry.

477904-66-8 CAPLUS

ANSWER 4 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) 2-Naphthaleneethanamine, 4-bromo-1-methoxy-a-methyl-, hydrochloride (SCI) (CA INDEX NAME)

477904-68-0 CAPLUS 1-Naphthalenol, 2-(2-aminopropyl)-, hydrochloride (9CI) (CA INDEX NAME)

● HC1

477904-73-7 CAPLUS 2-Naphthalenemethanol, α -[(1R)-1-aminoethyl]-1,4-dimethoxy-, (αS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

2

ANSWER 5 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) LIOH in aq. THF and workup.

400525-86-3P

RL: PAC (Pharmacological activity), SFN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)

(preparation of D-glutamic acid derivs. as inhibitors of glutamate racemase)
RN 400625-58-3 CAPLUS
CN D-Glutanic acid, 4-[(1-methoxy-2-naphthaleny1)methy1]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1171LE:
1NVENTOR(S):

Perparation of D-glutanic acid derivatives as inhibitors of glutanate racemase
De Dios, Alfonsos Equerra-Carrera, Jesus; McGee,
James Eugene: Martin, Jose Alfredo: Prieto, Lourdes;
Rubio-Esteban, Almudena: Smith, Michele Ceceil; Tebbe,
Mark Joseph
PATENT ASSIGNEE(S):
SOURCE:

DOCUMENT TYPE:

COEN: PIXCO2
Patent

DOCUMENT TYPE: LANGUAGE: Patent English 1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT	NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002		A2 A3	20020221	WO 2001-US22589	20010809
¥:	AE, AG, AL, CO, CR, CU, GM, HR, HU, LS, LT, LU,	AM, AT, CZ, DE, ID, IL, LV, MA,	, AU, AZ, , DK, DM, , IN, IS, , MD, MG,	BA, BB, BG, BR, BY, DZ, EC, EE, ES, FI, JP, KE, KG, KP, KR, MK, MN, MW, MX, MZ, SL, TJ, TM, TR, TT,	GB, GD, GE, GH, KZ, LC, LK, LR, NO, NZ, PL, PT,
RW:	UZ, VN, YU, GH, GM, KE, KZ, MD, RU,	ZA, ZW LS, MV, TJ, TM, MC, NL,	, MZ, SD, , AT, BE, , PT, SE,	SL, SZ, TZ, UG, ZW, CH, CY, DE, DX, ES, TR, BF, BJ, CF, CG,	AM, AZ, BY, KG, FI, FR, GB, GR,
AU 2001 PRIORITY APP	078945			AU 2001-78945 RS 2000-2055 US 2001-288361P WO 2001-US22589	20010809 A 20000810 P 20010503 W 20010809

OTHER SOURCE(S): MARPAT 136:200471

Compds. I [X is a bond, O, S, SO or SO2; Rl = (Cl-10)alkyl, (C2-10)alkenyl or -alkynyl, (C4-10)alkadienyl, carboxamido- or aminocarbonyl(Cl-8)alkyl which may be substituted by (C3-10)cycloalkyl or by one or two (un)substituted aromatic groups, provided that when X represents a bond, Rl can not represent a 3-phenyl-2-propenyl,3-(4-chlorophenyl)-2-propenyl,4-fluorobenzyl or 1-naphthylmethyl group) or their esters, amides or salts were prepared as inhibitors of glutamate racemase for use as antibiotics. Thus, (2R, 4S)-2-amino-4-(2-naphthyl)methylpentanedioic acid was prepared by alkylation of D-Et N-(tert-butoxycarbonyl)pyroglutamate with 2-naphthylmethyl bromide, followed by ring cleavage/deprotection using

L4 ANSWER 6 OF 55

ACCESSION NUMBER:
DOCUMENT NUMBER:
133:321687
1TILE:
AUTHOR(S):
AVERAGE SOURCE:
CORPORATE SOURCE:
CORPORATE SOURCE:
DOCUMENT SOURCE:
DOCUMEN

PUBLISHER: DOCUMENT TYPE:

LANGUAGE:

Journal English CASREACT 133:321687 OTHER SOURCE(S):

The electrochem. oxidation of methoxynaphthalenes, e.g., I, to afford the corresponding 5,8-dihydroxy-1,4-naphthoquinones, e.g. II, has been examined This method constitutes a new alternative and efficient route for the synthesis of the 5,8-dihydroxy-1,4-naphthoquinone nucleus. 302942-30-9

302942-30-9
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent) (cyclic voltammetry and electrochem. oxidation-deprotection of mathoxynaphthalenes in preparation of dihydroxynaphthoquinones) 302942-30-9
CAPUS
2-Naphthalenemethanol, 1,4,5,8-tetramethoxy-α-(nitromethyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1398:735923 CAPLUS
130:77422
130:77422
Phototransformation of napropamide
[N,N-diethyl-2-{1-naphthyloxy/proptonamide}] in aqueous
solution: influence on the toxicity of solutions
AQUED AUTHOR(S):
CORPORATE SOURCE:
SOURCE:
Lab. Photochimie Moleculaire et Macromoleculaire,
Universite Blaise Fascal-CNRS, Aubiere, P-63177, Pr.
Pesticide Socience (1998), 54(3), 253-257
COMEN: PSSCRG; ISSN: 0031-613X
John Viley & Sons Ltd.
Journal

PUBLISHER: DOCUMENT TYPE: LANGUAGE: Journal English

The main photoproducts formed in an aqueous solution of napropamide

The main photoproducts formed in an aqueous solution or napropamice diated in UV light are N.N-diethyl-2-(1-hydroxynaphthalen-2-yl)propionamide, N.N-diethyl-2-(4-hydroxynaphthalen-1-yl)propionamide and 1-naphthol. These account for c.60%, is and 10 of napropamide converted resp. No influence of the irradiation wavelength or of oxygen was observed The same products were obtained by irradiation of methanolic solms. The three identified products result from the cleavage of naphthoxy-carbon bond. The first two products imply a photo-Fries rearrangement. The influence of irradiation on the toxicity of the solms. was studied by the Hicrotox® test. The significant increase observed may be attributed partly to the formation of 1-naphthol. 131933-41-0

RE: ADV (Adverse effect, including toxicity); FMU (Formation, nonpreparative) (napropamide photoproduct in aqueous solution)

131933-41-0

CAPUS

Z-Naphthalenacetamide, N.N-diethyl-1-hydroxy-α-methyl- (9CI) (CA)

2-Naphthaleneacetamide, N,N-diethyl-1-hydroxy-α-methyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 55

ACCESSION NUMBER:

DOCUMENT NUMBER:

1998:207521 CAPLUS

129:12305

Three-dimensional quantitative structure-activity relationships of hallucinogenic phenylalkanamine and tryptamine derivatives. Studies using comparative molecular field analysis (COMFA)

Bewerle, Gerald, Kovar, Karl Artur, Schulze-Alexandru, Meike

CORPORATE SOURCE:

50URCE:

50URCE:

1016(6), 447-458

CODEN, GARDI, ISSN. 0931-8771

FUBLISHER:

FUBL

more than 0.8. The target parameter used was the hallucinogenic effect on humans, since this variable is of particular importance for research into addictive substances. It was possible to confirm the reliability of the COMFA anal. by using a second, independent phenylalkanamine data set. It was found that models with good predictive properties are obtained if up to ten components are taken into account. In a further step it was possible to include hallucinogenic tryptsmine derivs. in a common Qsar anal. with the phenylalkanamines and this in spite of their differing basic structures. The final model from that the COMFA plots were extracted

based on 148 compds. and permits precise inferences to be made concerning the relationships between structural elements and hallucinogenic effects. 207740-21-4 (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (QSAR of hallucinogenic phenylalkanamine and tryptamine derivs. using comparative mol. field anal.) 207740-21-4 CAPLUS 2-Naphthalenesthanamine, 1,4-dimethoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:561957 CAPLUS
DOCUMENT NUMBER: 129:297936
TITLE: The Frontier Orbital Phase Angles: Novel QSAR
Descriptors for Benzene Derivatives, Applied to
Phenylalkylamine Hallucinogens
Clare, Brian V.
CORPORATE SOURCE: Division of Science, Murdoch University, Murdoch,
6150, Australia
SOURCE: Journal of Medicinal Chemistry (1998), 41(20),
3845-3856
CODEN: JNCHAR: ISSN: 0022-2623
American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new empirical electronic descriptor, obtained from a MO calcn. and
applicable to benzene derivs., is proposed. It is shown that this
descriptor, the frontier orbital phase angle, correlates very strongly
with the phermacol. activity in humans of a large series of hallucinogens yet
reported, it is demonstrated that the phase of mixing of degenerate
frontier orbitals of benzene to form the frontier orbitals of the drug
results in the best electronic descriptor yet found for hallucinogenic
activity in phenylalkylamines.

IT 207740-21-4
RL: RAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(frontier orbital) phase angles as QSAR descriptors for benzene derivs.
applied to phenylalkylamine hallucinogens)

RN 207740-21-4 CAPLUS

REFERENCE COUNT:

41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1997:522248 CAPLUS DOCUMENT NUMBER: 127:234225 TITLE: Anionic homologous Fries rearra

127:234228
Anionic homologous Fries rearrangement of O-(2-methylary1) carbamates. A regiospecific route to benzo[b] furan-2(3H)-ones including an unnamed metabolite from Helenium species Kalinin, A. V.; Mtah, M. A. J.; Chattopadhyay, S.; Tsukazaki, M.; Wicki, M.; Nugen, T.; Coelho, A. L.; Kerr, M.; Snieckus, V. Guelph-Waterloo Center Graduate Work Chemistry, University Waterloo, Waterloo, ON, N21 3G1, Can. Synlett (1997), (7), 839-841
CODEN: SYNLES; ISSN: 0936-5214
Thieme AUTHOR (S):

CORPORATE SOURCE:

Thieme

PUBLISHER: DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(S):

LISHER: Thieme
UMENT TYPE: Journal
GUAGE: English
RS SOURCE(S): English
RS SOURCE(S): CASREACT 127:234225
A new LDA-mediated O + C carbamoyl migration provides a general and
efficient route to aryl acetamides as precursors to benzo- and
naphthofuranones, one of which serves as a starting material for a short
synthesis of naturally-occurring 3-hydroxy-3-methylene-6-methyl-2(3H)benzofuranone isolated from several Helenium species.
195210-92-39
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT
(Reactant or reasent)

(Reactant or reagent)
(preparation of benzofuranones by anionic homologous Fries rearrangement

O-(methylaryl)carbamates.) 195210-82-3 CAPLUS

2-Naphthaleneacetamide, N, N-diethyl-1-hydroxy- (9CI) (CA INDEX NAME)

Page 8

L4 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
1995:648033 CAPLUS
1717LE: 123:82959
ITITLE: 123:82959
INVENTOR(5): Preparation of 1-aryloxy-3-alkylamino-2-propanol nitrate esters as cardiovascular agents
PATENT ASSIGNEE(5): Prodesfarma, S. A., Spain
SOURCE: Prodesfarma, S. A., Spain
COURT TYPE: ANGUAGE: PRODUM
DOCUMENT TYPE: PRODUM
EARCH TYPE: PRODUM
TORRES PRODUM
PATENT INDEPNATION: 1

EAGLISH TYPE
PATENT INDEPNATION: 1

PATENT INDEPNATION: 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.			APPLICATION NO.	
EP 637583	A1	19950208	EP 1994-500111	
KP 637583	B1	19961218		
R: AT, BE, CH	, DE, DK	, FR, GB,	GR, IE, IT, LI, LU, I ES 1993-1721 AT 1994-500111 US 1994-265960	C, NL, PT, SE
ES 2065291	A1	19950201	ES 1993-1721	19930730
ES 2065291	B1	19951001		
AT 146453	B	19970115	AT 1994-500111	19940623
US 5502237	Α	19960326	US 1994-265960	19940627
NO 9402568	A	19950131	US 1994-265960 NO 1994-2568	19940707
NO 179746	В	19960902		
NO 179746	c	19961211		
AU 9467437	A1	19950209	AU 1994-67437	19940714
AU 666626		19960215		
CA 2128671 ZA 9405435	AA	19950131	CA 1994-2128671	
	A	19950511	ZA 1994-5435	
PL 175707	B1	19990129	PL 1994-304406	19940722
JP 07089910	A2	19950404	JP 1994-175400	19940727
JP 2777572		19980716		
HU 71813	A2	19960228	HU 1994-2229	19940729
HU 214827	В	19980629		
US 5639904	A	19970617	US 1995-514267	19950811
HORITY APPLN. INFO.:			US 1995-514267 ES 1993-1721	A 19930730
			US 1994-265960	A1 19940627
HER SOURCE (S):	MARPAT	123:82959		

Title compds. RlArOCH2CH(OH) CH2NHCHMe2 (R1 = R2Z(CH2)m where m = 1,2, Z = 0, CONH, CO2-ester function, R2 = C2-3 straight or branched chain alkyl having at least one nitroxy group as substituent, Ar = benzene ring when 2 is 0 or ester function, and a naphthalene ring when Z is CONN) are prepared 4-((2-Nitroxyethoxy)methyl]phenol in EtOH and NaOH was added to epichlorohydrin to give 2,3-epoxy-1-[-4-(2-nitroxyethoxy)methyl]phenoxypro

L4 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

ANSWER 11 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pane which was mixed with Me2CHME2 to give the title compd. I. Coronary
vasodilator and B1-adrenergic blocking activities were demonstrated.
Pharmaceutical formulations comprising the title compds. are given.
164340-23-48
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (aryloxy) (alkylamino) propanol nitrate esters as
cardiovascular agents)
164340-33-4 CAPLUS
2-Naphthalenescetamide, 1-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-N-[2(nitrooxy)ethyl]- (SCI) (CA INDEX NAME)

ΙT

164340-45-8
RL: RCT (Reactant), RACT (Reactant or reagent)
(preparation of (aryloxy) (alkylamino)propanol nitrate esters as
cardiovascular agents)
164340-45-8 CAPLUS

10636U-65-8 CAPLUS 2-Naphthaleneacetamide, 1-hydroxy-N-[2-(nitrooxy)ethyl]- (9CI) (CA INDEX NAME)

IT 164340-40-3P

164340-40-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (aryloxy) (alkylamino) propanol nitrate esters as cardiovascular agents)
164340-40-3 CARLUS
2-Naphthaleneacetamide, N-[2-(nitrooxy)ethyl]-1-(oxiranylmethoxy)- (9CI)
(CA INDEX NAME)

L4 ANSWER 12 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1171LE:
1171LE:
1172LET ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:

ACAPLUS COPYRIGHT 2005 ACS on STN
1995:305057 CAPLUS
122:80998
Preparation of HIV protease inhibitors
Reich, Siegfried H., Pino, Mark J., Nguyen, Dzuy T.,
Trippe, Anthony J.
PATENT ASSIGNEE(S):
SOURCE:
CODEN: PIXXD2
PATENT

Patent English

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT	NO.		KIND	DAT	B	,	APPL	ICAT	ION 1	NO.		I	ATE	
												-		
WO 941	5906		A1	199	40721		<i>t</i> o 1	994-	US420	D		1	9940	118
W:	AT, A	U, BB,	BG, I	BR, BY	, CA,	CH,	CN,	CZ,	DE,	DK,	ES,	FI,	GB,	GE,
	HU, J	Р, КР,	KR, 1	KŻ, LK	, LU,	LV,	MG,	MN,	MW,	NL,	NO,	NZ,	PL,	PT,
	RO, R	U, SD,	SE, S	SK, UA	, US,	UZ,	VN							
RW:	AT, B	E, CH,	DE, I	OK, ES	, FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,
	BF, B	J, CF,	CG, C	cı, ox	, GA,	GN,	ML,	MR,	NE,	SN,	TD,	TG		
CA 2153	3777		AA	199	40721		:A 1	994-	2153	777		1	9940	118
AU 9463	1229		A1	199	40815	7	AU 1	994-	61229	9		1	9940	119
AT 1791	164		E	199	90515	,	AT 1	994-	90719	99		1	9940	118
ES 2132	2383		T3	199	90816	F	S 1	994-	90719	99		1	9940	118
US 5714	1518		Α	199	80203	τ	JS 1	994-	32539	90		1	9941	027
PRIORITY API	LN. IN	FO.:				τ	JS 1	993-	5150		- 1	A2 1	9930	115
						ι	JS 1	993-	42261	1	- 2	A 1	9930	402
						ί	JS I	993-	99375	5		N 1	9930	730
							70 Î	994-	US420				9940	
ARTER COURSE	101.					•								

OTHER SOURCE(S): MARPAT 122:80898

Title compds. I (in claims as VI; c = 0-2; A' = 5-7-membered aromatic, carbocyclyl, heterocyclyl each of which can be substituted; R17 = H, halo, HO, (substituted) alkoxy, HS, thioether, OZM, alkyl, aryl, (substituted) amino, etc. R22 = (substituted) amino, etc. R22 = (substituted) amino, etc. R22 = (substituted) amino, gubstituted) amino, Q wherein B' = 5-7-membered aromatic, carbocyclyl,

ANSWER 12 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) heterocyclyl each of which can be substituted, d = 0-2, R18 = H, halo, HO, HS, etc., R21 = HZN, OZN, R3'R4'NC12 wherein Z = 0, S, R3', R4' = H, alkyl, cycloalkyl, aryl, etc., block the biol. activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate, are prepd. I are thus suitable for the treatment of the HIV virus known to cause AIDS. To Et3N and N-tert-butyl-N-(hydroxyethyl) (diphenyl-tert-butylsilyl) amine was added naphthoyl chloride to give a product which was converted in 5 steps to the title compd. II. I and II were screened by a variety of assays to det. their biol. utility.

160301-17-79

RL: RCT (Reactant): SFN (Synthetic preparation): PREF (Preparation): RACT

160301-17-79
RI: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation and reaction of, in preparation of HIV protease inhibitors)
160301-17-7 CAPUS
Benzoic acid, 2-[(2-hydroxy-3-[1-i[(trifluoromethyl)sulfonyl)oxy]-2naphthalenyl)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

ANSWER 13 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Novel 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanedicls of the formula RCH(OR1)CH(NR2R3)R4 or RCH2CR35(NR2R3)R4 wherein R is, e.g., I wherein RS is, e.g., Me(CH2)mC.tplbond.C, Me(CH2)mCHCGH, Me(CH2)mCH2CH2, WCGM4CH2(CH2)nc.tplbond.C, wherein m is 3 to 15, n is 0 to 12, and W and X are independently Mydrogen, hydroxy, alkyl, alkoxy, halogen, or trifluoromethyl, etc., Rl, R2, R3, RM, R35 are as defined in the specification, the optical isomers thereof, or the Pharmaceutically acceptable salts thereof, intermediates and processes for the preparation thereof, and methods of reducing inflammation and cell proliferation, and relieving memory dysfunction, and inhibiting bacterial and fungal growth are disclosed. Scopolamine-induced memory deficit reversal in mice: 27 and 33 at dose of 3.0 mg/kg, s.c., antiinflammatory activity as 4 decrease in ear pluy weight at 10 mg/ear in mice: 24-66%; antinepplastic activity as demonstrated in protein kinase C assay: protein kinase inhibitory activity 1050(mW) 6.7-48; antibacterial activity (MIC, mg/L): 1.56-12.50; antifungal activity (MIC, mg/L): 0.970-125.000. Pharmaceutical formulations were given.

167366-00-99 167366-03-29

RI: RCT (Reactant): STN (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent).

(1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compds. as anti-inflammatory agents).

167366-00-9 CAPLUS

Carbamic acid, diethyl-, 2-(2-amino-1,3-dihydroxypropyl)-7-(1-decynyl)-1-naphthalenyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME).

Absolute stereochemistry.

167366-03-2 CAPLUS 2-Naphthalenepropanol, β -amino-7-{1-decynyl}-1-hydroxy- γ -methoxy-, (RR. γ S)-rel-, (22)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CRN 167366-02-1 CMF C24 H33 N 03

Page 10

saeed

L4 ANSWER 13 OF 55
ACCESSION NUMBER:
1995:229454 CAPLUS
DOCUMENT NUMBER:
123:198625
1-alkyl, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflamatory agents
TWENTOR(5):
PATENT ASSIGNEE(5):
SOURCE:
DOCUMENT TYPE:
DOCUMENT TYPE:
L. I. Freed, Brian S. Herrinan, Gregory H.
U.S., 70 pp. Cont.-in-part of U.S. Ser. No. 840,236, abandoned.
CODEN: USXXXAN
LANGUAGE:
English

English 2

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5360811	A	19941101	US 1992-942908	19920910
IL 112775	A1	19951127	IL 1991-112775	19910311
ZA 9101805	A	19920226	ZA 1991-1805	19910312
PL 167266	B1	19950831	PL 1991-289390	19910312
PL 167570	B1	19950930	PL 1991-304111	19910312
RU 2024493	C1	19941215	RU 1991-4894900	19910313
RU 2074181	C1	19970227	RU 1992-5052218	19920720
US 5488063	λ	19960130	US 1994-247368	19940523
US 5488061	A	19960130	US 1994-247739	19940523
US 5519062	A	19960521	US 1994-247364	19940523
US 5550247	A	19960827	US 1995-425544	19950420
US 5557006	λ	19960917	US 1995-425529	19950420
US 5565584	A	19961015	US 1995-425531	19950420
US 5534636	A	19960709	US 1995-426452	19950421
US 5534640	Α	19960709	US 1995-426755	19950421
US 5571923	A	19961105	US 1995-426350	19950421
US 5574164	A	19961112	US 1995-426317	19950421
US 5597838	A	19970128	US 1995-426759	19950421
US 5614631	A	19970325	US 1995-426453	19950421
US 5977147	A	19991102	US 1996-639302	19960424
US 6500B49	B1	20021231	US 1999-237689	19990126
RIORITY APPLN. INFO.:			US 1990-492200	B2 19900313
			US 1990-596448	B2 19901012
			US 1990-632910	B1 19901224
			US 1992-840236	B2 19920224
			IL 1991-97510	A3 19910311
			US 1992-942908	A3 19920910
			US 1995-426759	A3 19950421
			US 1996-639302	A3 19960424
THER SOURCE(S):	MARPAT	123:198625		

L4 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

Absolute stereochemistry,

2

CRN 110-16-7 CMF C4 H4 O4

Double bond geometry as shown.

167366-01-0P 167366-02-1P

RE: SPN (Synthetic preparation), PREP (Preparation)

(1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compds. as anti-inflammatory agents)

167366-01-0 CAPLUS

Carbamic acid, diethyl-, 2-(2-amino-1,3-dihydroxypropyl)-7-(1-decynyl)-1-aphthalenyl ester, [S-(R*,A*)]- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

167366-02-1 CAPLUS
2-Naphthalenepropanol, β-amino-7-(1-decynyl)-1-hydroxy-γ-methoxy-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) L4 ANSWER 14 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1171LE:
INVENTOR(5):
PATENT ASSIGNEE(5):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
FAIGHT ACS. NUM. COUNT:
PATENT TOROMATION:
COURT TYPE:
FAMILY ACC. NUM. COUNT:
FAMILY ACC. NUM DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9415608 A1 19940721 WO 1994-US419 19940118

W: AT, AU, BB, BG, BR, BY, CA, CH, CR, CZ, DB, DK, ES, FI, GB, GE,
HU, JF, KF, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, FL, FT,
RO, RU, SD, SE, SK, UA, US, UZ, VN

RW: AT, EE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, FT, SE,
BF, BJ, CF, CG, CI, CH, GA, GM, ML, MR, NE, SN, TD, TG

CA 2153777 AA 19940721 CA 1994-2153777 19940118

EF 695184 A1 19940971 CA 1994-60871 19940118

EF 695184 B1 19940121 CA 1994-907199 19940118

EF 695184 B1 19990126 ES 1994-907199 19940118

ES 2132383 T3 19990126 ES 1994-907199 19940118

ES 2132383 T3 19990126 US 1994-225340 19941027

PRIORITY APPLN. INFO: US 1993-12561 A2 19930115

US 1963-95075 A 199301002

FRIORITY APPLN. INFO: WARPAT 121:255414 DATE 19940721 PATENT NO. KIND APPLICATION NO.

OTHER SOURCE(S): MARPAT 121:255414

L4 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

R14R15R16Z w2R3R4 (CR5R6) nUR9R10 (YR7R8) m R1R2w1 XR11R12R13

AB Title compds. [I; A, B = (substituted) carbocyclyl, heterocyclyl, (fused) polycyclyl; n, m = 0-6; X, Y, Z, Wl, WZ = N, O, C, S, Se; U = C, B, Se, S, P; R1-R4 = null, H, alkyl, aryl; ≥ 1 of R1, R2 can form a ring with Wl; ≥ 1 of R3, R4 can form a ring with Wl; R5-R8 = null, H, halo, OH, (substituted) alkoxy, aryloxy, N, alkyl, aryl; R9, R10 = null, H, halo, OH, (substituted) alkoxy, aryloxy, N, alkyl, aryl; c0; R11-R16 = null, H, halo, OH, (substituted) alkoxy, aryloxy, N, alkyl, aryl; c0; R11-R16 = null, H, halo, OH, (substituted) alkoxy, aryloxy, N, alkyl, aryl; ≥ 1 of R11-R16 can form a ring with Z; with provisos], were prepared Thus, 2-MeCSH4COCL was coupled with We3CNICKICH2OSYPh2CMe3. This in THF containing disopropylamine at -78 'was treated with sec-Buli and then ethylene oxide at -78 'room temperature to give 32 * (ROCH2CH2) CSH4CONCMe3CH2CH2OSYPh2CMe3. This was oxidized to the acid with pryidinjum dichromate in DMF (32*) and the acid was anidated with HDM+OMS-RCI uning BOP and Hunig's base to give 59 * 2- Me(MeO)MCCME]CSH4CNCMe3CH2CH2OSYPh2CMe3. The latter was coupled with 2-MeCSH4CONCMe3CH2CH2OH using disopropylamine/sec-Buli as above to give after NaRH4 reduction and desilylation, title compound II. II inhibited

HIV-1 protease with ICSO = 1.03 MM. I were active against HIV-induced killing of CEM cells at ≥ 0.48 µy/mL.

II 160301-17-79

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

160301-17-79
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hydroxyalkyl) arylamides as HIV protease inhibitors)
160301-17-7 CAPUS
Benzoic acid, 2-[(2-bydroxy-3-[1-[((crifloorcmethyl) sulfonyl) cxy]-2-naphthalenyl]propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:191311 CAPLUS
DOCUMENT NUMBER: 120:191311 TAPLUS
INTENTOR(S): Fujita, Takashir yoshioka, Takaoy Horikoshi, Hiroyoshir yoshioka, Shinji
SOURCE: SAKYO Co., Ltd., Japan
EUR. PAT. APPL., 69 pp.
CODEN: EFYKUM
DOCUMENT TYPE: Patent
LANGUAGE: Fujita, Company
PAMILY ACC. NUM. COUNT: 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.		DATE		
EP 543662 EP 543662 EP 543662	AZ	19930526	KP 1992-310625	19921120
EP 543662	A3	19930811		
EP 543662	B1	19960918		
R: AT, BE, CH,	DE, DK	, E5, FR,	GB, GR, IE, IT, LI, LU,	MC, NL, PT, SE
NO 9204440	V	19930521	NO 1992-4440	19921118
NO 179246	В	19960528		
NO 179246	C	19960904		
ZA 9208960	Α.	19930519	ZA 1992-8960 CA 1992-2083323 CZ 1992-3436 CZ 1995-345 RU 1992-4433 AU 1992-28493	19921119
CA 2083323	AA	19930521	CA 1992-2083323	19921119
CZ 280328	86	19951213	CZ 1992-3436	19921119
CZ 280820	B6	19960417	CZ 1995-345	19921119
RU 2095344	Cl	19971110	RU 1992-4433	19921119
AU 9228493	A1	19930527	AU 1992-28493	19921120
AU 055689	BZ	19950105	CN 1992-114826	******
CN 1073428	Δ.	19930623	CN 1992-114826	19921120
R: AT, BE, CH, NO 9204440 NO 179246 VA 179246 VA 9208960 CA 208323 CZ 280328 CZ 280820 CX 20820 CX 1073428 CX 1034497 JP 06025118 HU 66816 CX 1106396 CX 1033750 AT 143002 ES 2094308 IL 110804	В	199/0409	10 1000 211035	10001100
JP 06025118	AZ	19940201	JP 1992-311975	19921120
HI 00810	AZ.	19950130	HU 1992-3638	19921120
CN 1106396	^	19950809	CN 1994-118086	
CN 1033750	В.	19970108	AT 1992-310625 BS 1992-310625 IL 1992-10804 IL 1992-103825 KR 1992-21899 US 1994-282579 KR 1994-21931	10001100
A1 143002		19901015	A1 1992-310625	19921120
ES 2094308	13	19970116	ES 1992~310625	19921120
IL 110804 IL 103825 KR 149679 US 5977374	Vī	19970713	IL 1992-110804	19921120
IL 103825	W1	19980405	IL 1992-103825	19921120
KR 1496/9	BI	19981015	KR 1992-21899	19921120
KR 161552	Α.	19991102	US 1994-282579	19940729
			KK 1994-21931	19940831
RU 2081113	, 01	19970610	RU 1994-36004 AU 1994-77518	19940930
AU 9477518	W1	19950112	WO 1994-1/218	19941027
AU 6/000/	52	19960627	UG 1005 270070	10050104
05 5576340	^	19901119	US 1995-378879 US 1995-478610	19950126
US 3033534	^	19970603	CN 1996-107153	19950607
CN 1151401	~	19970611	CN 1996-10/153	19960621
CN 1034846	B	10070726	JP 1997-5361	10070116
AU 9477518 AU 9477518 AU 670007 US 5576340 US 5635534 CN 1151401 CN 1054846 JP 09188669 JP 2991985	A2	19970722	OF 1331-2361	13310116
PRIORITY APPLN. INFO.:	DZ	13331220		x 10011120
PRIORITI AFPLA. INFO.:			JP 1991-304581 JP 1992-311975 KR 1992-21899	M 1331112U
			VP 1002-21000	MJ 1332112U
			VV 1335-51933	W2 1225115A

ANSWER 15 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

L4 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 1992-979180 B1 19921120

US 1994-178465 B3 19940106

US 1995-178479 A3 19950126

OTHER SOURCE(S): CASREACT 120:191311, MARPAT 120:191311

Compds. I [R = H, Me, HOCH2; Rl = substituted alkyl [substituents may be COZH, C2-7 alkoxy- or aryloxycarbonyl, aralkoxycarbonyl, [di]alkyl- or hydroxycarbomyl, carbamyl, OH, carboxylic acyloxy, and 2,4-dioxochazolidin-5-yl groups]; RZ, R3 = H, halo, OH, alkoxy carboxy, alkoxycarbonyl, alkyl, NO2, haloalkyl, substituted alkyl, X = 0, 5; Ar = Ph or naphthyl or their derivs. containing up to three substituents

including
halo, OH, HOCH2, alkoxy, alkyl, haloalkyl, aliphatic carboxylic acyloxy
group, or aralkyloxy containing a C1-3 alkyl chain substituted by 1 or 2

groups containing 6-10 ring C atoms and which are substituted with halo, C1-4

153293-16-4

RL: RCT (Reactant), RACT (Reactant or reagent)
(preparation as antidiabetic agent)
153293-16-4 CAPLUS
Benzenepropanoic acid, 4-[2-[[2-(4-bromo-1-hydroxy-2-naphthalenyl)-2-hydroxyethyl]amino]propoxy]-β-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 55

ACCESSION NUMBER:
DOCUMENT NUMBER:
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
117:7945
11

Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 470600	A1	19920212	EP 1991-113282	19910807
EP 470600	B1	19970507		
R: AT, BE, CH,	DE, DK	, ES, FR,	GB, GR, IT, LI, LU, N	L. SE
CA 2048713	AA	19920211	CA 1991-2048713	19910808
IL 99122	A1	19970218	IL 1991-99122	19910808
AU 9181762	A1	19920213	AU 1991-81762	19910809
AU 647163	B2	19940317		
HU 58300	A2	19920228	HU 1991-2666	19910809
ZA 9106297	A	19920429	ZA 1991-6297	19910809
BR 9103426	A	19920519	BR 1991-3426	19910809
JP 04230670	A2	19920819	JP 1991-225025	19910809
CZ 279334	B6	19950412	CZ 1991-2470	19910809
PL 169439	B1	19960731	PL 1991-291383	19910809
CN 1058776	λ	19920219	CN 1991-105501	19910810
US 5469751	Α	19951121	US 1993-126154	19930923
PRIORITY APPLN. INFO.:			CH 1990-2603	A 19900810
			CH 1991-390	A 19910208
			US 1991-741716	B3 19910807
			US 1992-910939	B1 19920719
			US 1993-15079	B1 19930208

OTHER SOURCE(S): GI For diagram AB Title compde MARPAT 117:7945

US 1993-15079 B1 19930208

BR SOURCE(S): MARPAT 117:7945

For diagram(s), see printed CA Issue.
Title compds. I (RI = H, (substituted) C1-5 alkyl, (halo)-C2-7 alkenyl,
C3-7 cycloalkyl, halo, C2-6 alkynyl, R2 = H, Ho, (substituted) C1-5 alkyl,
C1-4 alkoxy, halo, C2-6 alkynyl, R2 = H, Ho, (substituted) C1-5 alkyl,
R3R9N, R1089C:N wherein R3 = H, C1-5 alkyl, P6D, R7S, wherein R9 = C1-5 alkyl, R10 = H, C1-5 alkyl, R6 = C1-5 alkyl, R500, R7S, wherein R9 =
C1-5 alkyl, R10 = H, C1-5 alkyl, C3-7 cycloalkyl; R5 = halo, C1-3 alkyl; R4, R8 =
H, (substituted) C1-3 alkyl; C3-7 cycloalkyl; R5 = halo, C1-3 alkyl; C1-3
alkylN, etc.; m, n = 0-3]. To a solution of 4,5-dichloro-6-ethylpyrimidine
in BUGH were added 1-p-naphthylethanamine and EXTN to give after
workup 4 (1-p-naphthylethylamino)-5-chloro-6-ethylpyrimidine (II).
Il was effective in controlling Pythium ultimum on sugar best and corn.
141625-49-27
RL: AGR (Agricultural use) BAC (Biological activity or effector, except
adverse) BSU (Biological study, unclassified); SPN (Synthetic
preparation); BIOL (Biological study); PREF (Preparation); USES (Uses)
(preparation of, as pesticide)
141625-49-2 CAPLUS
4-Pyrimidinamine, 5-chloro-6-ethyl-N-(2-(1-methoxy-2-naphthalenyl)ethyl](9C1) (CA INDEX NAME)

ANSWER 16 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

LA ANSWER 17 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1192:173958 CAPLUS
116:173958
1171LE:
Synthetic studies on indoles and related compounds.
XXIX. Attempted syntheses of benz[f]indoles by cyclization reactions
AUTHOR(5):
Watanabe, Toshiko: Takahashi, Hiroyuki, Kanakura, Hiroyuki, Sakaquehi, Susumun Osaki, Mesakor Toyama, Satoru, Mizuna, Yuka, Ueda, Ikuko, Murakani, Yasuko CORPORATE SOURCE:
SOURCE:
SOURCE:
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
DOCUMENT TYPE:
LANGUAGE:
DOCUMENT TYPE:
LANGUAGE:
Beglish

CAPLUS COPPILA 2005 ACS on STN
1992:173958
CAPLUS
Synthetic studies on indoles and related compounds.
XXIX. Attempted syntheses of benz[f]indoles by cyclization reactions
Satoru, Mizuna, Yuka, Ueda, Ikuko, Murakani, Yasuko
Chemical & Pharmaceutical Bulletin (1991), 39(12),
3145-52
CODEN: CPETAL, ISSN: 0009-2363
Journal
English

DOCUMENT TYPE: LANGUAGE: GI

Syntheses of benz[f]indoles from 1,2-disubstituted naphthalene derivs. by means of cyclization reactions were attempted. The Fischer indolization of naphthylhydrazones I (R - Me, Cl., NO2) gave only benz[e]indole derivs. II (RI - H, Cl) or decomposed products, and the desired 9-substituted benz[f]indole was not produced. On the other hand, the Fischer indolization of 2-methoxy-1-naphthylhydrazone III gave Et 5-chlorobenz[g]indole-2-carboxylate IV.
139979-15-0
RL: SFN [Synthetic preparation), PREP (Preparation) (preparation of)
139979-15-0 CARUUS
2-Naphthalenepropanoic acid, α-azido-β-hydroxy-1-methoxy-, ethyl ester (SCI) (CA INDEX NAME)

IT

L4 ANSWER 18 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1111E:
AUTHOR(\$5):
CORPORATE SOURCE:
DOCUMENT SOURCE:
AUTHOR(\$6):
CORPORATE SOURCE:
DOCUMENT TYPE:

CAPLUS COPPRIGHT 2005 ACS on STN
1991:116851 CAPLUS
114:116851
Aqueous photolysis of napropamide
Chang, Lydia L.; Giang, Benjamin Y.; Lee, Kuo Shin;
Tseng, Chien K.
Agric. Prod. Div., ICI Americas Inc., Richmond, CA,
94804-0023, USA
Journal of Agricultural and Food Chemistry (1991),
39(3), 617-21
CODEN: JAFCAU, ISSN: 0021-8561

CODEN: JAFCAU, ISSN: 0021-8561

DOCUMENT TYPE: Journal

AB Photolysis of napropamide was examined at 25° in aqueous solution buffered at pH 7 by using radiation from a xenon arc lamp. The pseudo-first-order photolysis half-life and rate constant were 5.7 min and 1.2 + 10-1 min-1, resp. Three major photodegrdn. products were produced in yields up to 20, 27, and 94. The 3 photodegrdn. products were produced in yields up their structures identified by NMR and mass spectrometry.

IT 131933-41-0 131933-42-1

RL: BIOL (Biological study) (napropamide photolysis product)

RN 131933-41-0 CAPIUS

CN 2-Naphthaleneacetamide, N,N-diethyl-1-hydroxy-α-methyl- (9CI) (CA INDEX NAME)

131933-42-1 CAPLUS {1,1'-Binaphthalene]-3,3'-diacetamide, N,N,N',N'-tetraethyl-4,4'-dihydroxy- α,α' -dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
1990:459385 CAPLUS
113:59385
TITLE:
Enantioselective catalysts having a new zirconium trichloride-Lewis acid with dibornaneannulated cyclopentadienyl ligand
Erker, Gerhard: Van der Zeijden, Adolphus A. H.
Inst. Org. Chem., Univ. Weerzburg, Weerzburg, D-8700, Gernany
Angewandte Chemie (1990), 102/51, 543-5

Angewandte Chemie (1990), 102(5), 543-5 CODEN: ANCEAD; ISSN: 0044-8249 SOURCE:

DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(5): Journal

JMENT TYPE:

Journal
JUAGE:

German

SUNCE(S):

CASREACT 113:59385

Por diagram(s), see printed CA Issue.

Synthesis of title complex I (MLn = ZrCl3) as enantioselective catalyst for condensation of CH3COCCZET with 1-naphthol is described. Thus, condensation of 2 equivalent of 2-bornen-2-yllithium with HCCZET followed by cyclization with KHSO4 gave substituted cyclopentadienyl ligand system which on deprotonation with BLLI-ELO gave I [MLn = Li(CEL2]). Treatment of ZrCl4 or HfCl4 with I (MLn = Li(CEL2]) in PhMe gave 404 I (MLn = ZrCl3, HfCl3). Condensation of 1-naphthol with CH3COCCZET in the presence of catalyst (IR, 45, I'R, 4'5)-I (MLn = ZrCl3) in HZO-CHZCl2 gave R-lactic acid ester II in 534 yield with 84.1 enantiomeric excess. The mechanism of the reaction is discussed.

126035-90-3P 126033-91-4P

RL: SPN (Synthetic preparation), PREP (Preparation)

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) 126035-90-3 CAPLUS

2-Naphthaleneacetamide, α,1-dihydroxy-α-methyl-N-(1-phenylethyl)-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

126035-91-4 CAPLUS 2-Naphthaleneacetamide, α,1-dihydroxy-α-methyl-N-(1-phenylethyl)-, (R*,S*)- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
1999:173639 CAPLUS
110:173639
Synthetic studies on nogalamycin congeners. II.
Chiral synthesis of the CEEF-ring system of
nogalamycin
AUTHOR(S):
KAWASSKI, Motoji, Matsuda, Fuyuhiko; Terashima, Shiro
CORPORATE SOURCE:
Sagami Chem. Res. Cent., Kanagawa, 229, Japan
Totrahedron (1989), 44(18), 5713-25
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE:
LANGUAGE:
COTHER SOURCE(S):
GI
CASREACT 110:173639

LANGUAGE: OTHER SOURCE(S): GI

OCH20Me _OSiMe2CMe3 11

The CDEF-ring system I of nogalamycin was prepared in several steps starting with the reaction of ketone II with 1,4,5,8-tetramethoxynaphthalene. 105827-47-29
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT

RL: RCT (Reactant): SFN (Synthetic preparation): FRAT (Freparation): Reactant or reagent (Reactant or reagent) (preparation and desilylation of) 105827-47-2 CAPLUS L-Glucitol, 3,6-dideoxy-1-0-[(1,1-dimethylethyl)dimethylsilyl]-3-[(methoxycarbonyl)methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (SCI) (CA INDEX NAME)

105827-48-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or respect) (preparation and oxidation of) 105827-48-3 CAPLUS

Page 14 saeed ANSWER 19 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ANSWER 20 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) L-Glucitol, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino)-2,4-bis-O-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9C1) (CA INDEX NAME)

120143-13-7P

120143-13-79
RL: SPN (Synthetic preparation), PREP (Preparation)
(preparation of)
120143-13-7 CAPLUS
D-Iditol, 3,6-dideoxy-1-0-[(1,1-dimethylethyl)dimethylsilyl]-3[(methoxycarbonyl)methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 21 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1988:570804 CAPLUS
109:170804
A process for the preparation of 6-(1,4-dimethoxy-5,8-dioxonaphthalen-2-yl)-3,4,5,6-tetrahydro-2H-pyran derivatives as neoplasm inhibitors
Terajima, Atsuro, Kawasaki, Mototsuchi; Matsuda, Puyuhiko; Yamada, Kaoru
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:

COEN: JKOKAF
Patent

DOCUMENT TYPE: Patent Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. APPLICATION NO. KIND DATE DATE JP 62153281 JP 05086787 PRIORITY APPLN. INFO.: A2 B4 19870708 19931214 JP 1985-292240 19851226 JP 1985-292240 19851226

The title compds. (I; R = protecting group), useful as neoplasm inhibitors, are prepared Naphthyltetrahydropyran derivs. II [prepared from (silyloxyhexanone derivative (-)-III in six steps) in \$EOH was treated with squeous (NH4)2Ce(NO3)6 at -40° to give 21% I (R = MeOCH2) which showed an ICSO of 0.14 μ /mL against p388 leukemia cells. 105827-47-2P

RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT

ANSWER 21 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ANSWER 21 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Resectant or reagent)
(Prepn. and deprotection of, as intermediate for neoplasm inhibitors)
10527-47-2 CAPLUS
L-Glucitol, 3,6-dideoxy-1-0-{(1,1-dimethylethyl)dimethylsilyl}-3[(methoxycarbonyl)methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8tetramsthoxy-2-maphthalenyl)- (9CI) (CA INDEX NAME)

111224-40-9P

RE: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation and etherification of, as intermediate for neoplasm

(preparation and determination)
inhibitors)
RN 111224-40-9 CAPLUS
CN L-Glucose, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI)
INDEX NAME)

116592-97-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and self-cyclocondensation of, pyran derivative from, in paration of

aration of
neoplasm inhibitors)
116592-97-3 CAPLUS
L-gluco-Heptitol, 2,4,7-trideoxy-4-[(methoxycarbonyl)methylamino]-3,5-bisO-(methoxymethyl)-6-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA
INDEX NAME)

L4 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1988:549325 CAPLUS DOCUMENT NUMBER: 109:149325

DOCUMENT NUMBER: TITLE: Access to (aminomethyl)benzo[g]isoquinoline-5,10-diones. Abnormal substitution in the Bischler-Napieralski reaction of 1,4-

dimethoxynaphthalenes Croisy-Delcey, Martine: Huel, Christiane: Bisagni, AUTHOR (S):

Lab. Synth. Org., Inst. Curie, Orsay, 91405, Fr.
Journal of Heterocyclic Chemistry (1988), 25(2), 661-5
CODEN: JHTCAD, ISSN: 0022-152X
Journal CORPORATE SOURCE: SOURCE:

DOCUMENT TYPE:

LANGUAGE: OTHER SOURCE(S): French CASREACT 109:149325

Bischler-Napieralski reaction of [(acylamino)ethyl]dimethoxynaphthalene derivs. I (R = H, Rl = H, phthalimido) gives the expected dihydrobenzoisoquinolines II (same Rl). However, I (R = CMe, Rl = H, phthalimido) give only aromatized regioisomers III, and I (R = Rl = H) gives .apprx.308 III. Cyclocondensation of isoquinolinedones IV (R2 = H, NRAc, NRCOCHE, NRCOCHEZ) with Aco(CHCH) 20Ac gives 39-54% azaanthraquinones V (same R2). 116577-63-91 11

Acetamide, N-[2-(1,4-dimethoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX

14 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

СН2-СН2-МНАС

116577-59-4 CAPLUS Acetamide, N-{2-{1,4,8-trimethoxy-2-naphthalenyl}ethyl}- (9CI) (CA INDEX NAME)

CH2-CH2-NHAC

116577-63-0 CAPLUS
2H-1soindole-2-acetamide, N-[2-[1,4-dimethoxy-2-naphthalenyl]ethyl]-1,3-dibydro-1,3-dioxo-(9C1) (CA INDEX NAME)

116577-64-1 CAPLUS
2H-Isoindole-2-acetamide, 1,3-dihydro-1,3-dioxo-N-[2-{1,4,8-trimethoxy-2-naphthalenyl}ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1988:528643 CAPLUS
109:128643
A new counaarin synthesis based on the aromatic metalation reaction
AUTHOR(S):
AUTHOR(S):
Harvey, Ronald G., Cortez, Cecilis; Ananthanarayan, T.
P.; Schmolka, Sanford
Ben May Inst., Univ. Chicago, Chicago, IL, 60637, USA
Tetrahedron Letters (1987), 28(49), 6137-8
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE:
LANGUAGE:
English

DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(S): GI

English CASREACT 109:128643

116137-99-6P
RL: SPN (Synthetic preparation), PREP (Preparation) (preparation and demethoxymethylation and ring closure of) 115560-75-3 CAPLUS
2-Naphthalenepropanamide, β-hydroxy-1-(methoxymethoxy)-N, N-dimethyl-(9CI) (CA INDEX NAME)

MeO-CH2-0 OH O | |CH-CH2-C-NMe2

115560-76-4 CAPLUS 2-Anthracenepropanamide, \$\theta\$-hydroxy-1-(methoxymethoxy)-N, N-dimethyl-(9C1) (CA INDEX NAME)

Page 16

saeed

L4 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

115560-78-6 CAPLUS 2-Pyrenepropanamide, β -hydroxy-1-(methoxymethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

115560-81-1 CAPLUS
2-Pyrenepropanamide, β-hydroxy-1-(methoxymethoxy)-N,N,β-trimethyl- (9CI) (CA INDEX NAME)

116137-97-4 CAPLUS 2-Pyrenepropanamide, β -hydroxy-3-(methoxymethoxy)-N,N, α -trimethyl- (9CI) (CA INDEX NAME)

116137-98-5 CAPLUS 2-Pyrenepropanamide, β -hydroxy-3-(methoxymethoxy)-N,N, α , β -tetramethyl- (9CI) (CA INDEX NAME)

ANSWER 23 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

116137-99-6 CAPLUS 2-Anthracenepropanamide, β-hydroxy-1-(methoxymethoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)

ANSWER 24 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

115560-76-4 CAPLUS 2-Anthracemepropanamide, β-hydroxy-1-(methoxymethoxy)-N,N-dimethyl-(9CI) (CA INDEX NAME)

115560-78-6 CAPLUS 2-Pyrenepropanamide, β-hydroxy-1-(methoxymethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

115560-81-1 CAPLUS 2-Pyrenepropanamide, \(\beta\)-hydroxy-1-(methoxymethoxy)-N,N,\(\beta\)-trimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 55
CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
1988:492720 CAPLUS
109:92720
A new counsarin synthesis and its utilization for the synthesis of polycyclic counsarin compounds with anticarcinogenic properties

AUTHOR(S):
Harvey, Ronald G., Cortez, Ceclia, Ananthanarayan, T. F., Schoolka, Sanford
CORPORATE SOURCE:
SOURCE:
DOCUMENT TYPE:

DOCUMENT TYPE:

DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(S): English CASREACT 109:92720

A novel synthesis of coumarins based on the ortho-directed metalation of methoxymethyl phenolic ethers with alkyllithium reagents is described. The method entails reaction of the ortho-lithiated intermediates with DMF to yield the corresponding ortho aldehydes. Reaction of the latter with LICHZCONMe2 affords the addition products which, on heating in refluxing AcOH, undergo smooth conversion directly to coumarins. A wide range of coumarins containing substituents in the 6- and 7-positions as well as the polycyclic coumarin analogs of phenanthene, bens [a]anthracene, and benzo[a]pyrene, and their Me-substituted derivs. were prepared by appropriate modifications of this method. Freliminary assays of biol. activity indicate that the benzo[a]pyrene coumarin analog I is a potent inhibitor of tumor induction when administered prior to the carcinogen 7,12-dimethylbenz[a]anthracene, and I, is itself devoid of tumorigenic activity. The polycyclic coumarins hold promise as agents for the chemoprevention of cancer.

115560-31-39 115560-76-49 115560-78-69
11550-81-19
RE: RCT (Reactant), SPN (Synthetic preparetion), PREP (Preparation), RACT

115560-81-1P
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (preparation and intramol. cyclocondensation reaction of, coumarin derivative
from)
RN 115560-75-3 CAPLUS
CN 2-Naphthalenepropanamide, β-hydroxy-1-(methoxymethoxy)-N,N-dimethyl-(9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 1988:422843 CAPLUS DOCUMENT NUMBER: 109:22843

109:22843
Preparation of 4-amino-3,5-bis(methoxymethoxy)-6-methyl-6-(1,4,5,8-tetramethoxynaphthalen-2-yl)-3,4,5,6-tetrahydro-2H-pyran derivatives as neoplasm inhibitor decremediate. TITLE:

intermediates

Intermediates
Terajima, Atsuro; Kawasaki, Motoshi; Matsuda, Fuyuhiko
Sagami Chemical Research Center, Japan
Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
Patent INVENTOR (S): PATENT ASSIGNEE (S): SOURCE:

DOCUMENT TYPE:

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE JP 62153282 PRIORITY APPLN. INFO.: JP 1985-292241 JP 1985-292241 A2 19870708 19851226

The title compds. I [when R1 = MeO2C, R2R3 = 0 or one of R2 and R3 = H and another one (protected) OH when R1 = Me, one of R2 and R3 = H and another one = protected hydroxy], useful as intermediates for anticancer agents (which are also prepared), are prepared A solution of (-)-II (preparation by the composition of the composition

) in CH2C12 was treated with a mixture of oxalyl chloride and DMSO in CH2C12 at -60° and subsequently with Et3N at 0° to give 91% I (R1 -

ANSWER 25 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) COZNer R2B3 - 0) which was converted to (+)-III with seven steps. III showed ICSO at 0.10 µd/pL against mice leukemie cells F388. 105827-48-3P 113350-49-5P

103827-48-3P 113350-49-5P
RL: SFN (Synthetic preparation), PREP (Preparation)
(preparation of, as intermediate for anticancer agent)
105827-48-3 CAPLUS
L-Glucitol, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-maphthalenyl)- (9CI)
INDEX NAME)

113350-49-5 CAPLUS
D-Allitol, 1,4-dideoxy-6-0-((1,1-dimethylethyl)dimethylsilyl]-4[(methoxycarbonyl)methylamino]-3,5-bis-0-(methoxymethyl)-2-C-(1,4,5,8tetramethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

ANSWER 26 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) (prepn. and hydrolysis of) 105827-47-2 CAPLUS 105827-47-2 CAPLUS L-Glucitol, 3.6-dideoxy-1-0-[(1,1-dimethylethyl)dimethylsilyl]-3-[(methoxycarbonyl)methylamino]-2.4-bis-0-[methoxymethyl)-5-C-(1,4,5,8-teramethoxy-2-naphthalenyl)- (SCI) (CA INDEX NAMS)

105827-48-3P
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (preparation and lactonization of)
105827-48-3 CAPLUS
L-Glucitol, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA INDRY NAME)

L4 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1988:112732 CAPLUS DOCUMENT NUMBER: 108:112732 108:112732
Preparation of 4-{bis(trialkylsiloxy)mathylene}-1-mathyl-3-mathylene-1-cyclohexene derivatives as anticancer intermediates
Terajina, Atsuror Kawasaki, Motoshi; Matsuda, Fuyuhiko Sagami Chemical Research Center, Japan
Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JOCKAF
Patent INVENTOR (S): PATENT ASSIGNEE (S): SOURCE: DOCUMENT TYPE: LANGUAGE: Patent Japanese FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE JP 62153294
PRIORITY APPLN. INFO.: A2 19870708 JP 1985-292243 JP 1985-292243 19851226

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The title compds. (I, Rl, R2, R3 = alkyl), useful as intermediates for anticancer anthracycline derivs., are prepared BuLi in hexane was added to solution of (He2CH) ZNH in THF at -40°, followed by acid III in THF and He3SiCl at -78°, and the solution stirred at 30° to give I [Rl = R2 = R3 - Hs], which (0,50 mmol) was treated with (+)-(2R, 3S, 4R, SR, GR)-IV in THF at 20° to give 85% adduct V. V was aromatized and hydrolyzed to give (+)-nogarene (II).

111224-40-9P
REL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
(preparation and etherification of)
111224-40-9 CAPLUS
L-Glucose, 3,6-dideoxy-3-{(methoxycarbonyl)methylamino]-2,4-bis-O-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

105827-47-28 105827-47-2F RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 1987:618008 CAPLUS DOCUMENT NUMBER: 107:218008

Preparation of 2,6-epoxy-3,4,5,6,1,12-hexahydro-ZH-naphthaceno[1,2-b]oxocin-9,16-dione derivatives as anticancer agents and intermediates for nogarene derivatives

derivatives Terajima, Atsuro, Kawasaki, Hotoshi, Hatsuda, Fuyuhikor Yamada, Kaoru Sayami Chemical Research Center, Japan Jpn. Kokai Tokkyo Koho, 21 pp. CODEN: JXOKAF INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

Patent

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

APPLICATION NO. PATENT NO. KIND DATE DATE JP 62153290 PRIORITY APPLN. INFO.: A2 19870708 JP 1985-292244 JP 1985-292244 19851226

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anticancer anthracyclines (I; R1 - H, protecting group), which can be converted into optically active nogarene derivs. (II) by dehydrogenation, were prepared in 12 steps from 3,5,6-trihydroxy-4-amino-2-hexanone derivative.

III. Cycloaddn. reaction of 4-[bis(trimethylsilyloxy)methylene]-1-methyl-3-methylene-1-cyclohexene with a naphthleno[1,2-b]oxocin-9,12-dione

derivative

IV, which was prepared in 11 steps via condensation of III with
1,4,5,8-tetramethoxynaphthalene, in THF at room temperature for 30 min

followed

by treatment with aqueous HCl and then saturated aqueous NaHCO3 gave 85% I

(R1 - Ac)

(Y) which was treated with DL-camphorsulfonic acid and

2,3-dichloro-5,6-dicyano-1,4-benzoquinone in benzene under reflux to give

85% II (R1 - Ac). V and I (R1 - H) in vitro show IC50 of 0.5% and 0.13

p4/ML resp. in mouse leukemia P38% cells.

II 111224-40-pp

111224-40-9P
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT
(Reactant or reagent)
(preparation and alkylation of, with chloromethyl He ether)
111224-40-9 CAPLUS
L-Glucose, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-nephthelenyl)- (9CI) (CA
INDEX NAME)

(Continued)

ANSWER 27 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

ΙT

105827-47-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation of)
105827-47-2 CAPUS
L-Glucitol, 3,6-dideoxy-1-0-[(1,1-dimethylethyl)dimethylsilyl]-3[(methoxycarbonyl)methylamino]-2,4-bis-0-(mathoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (SCI) (CA INDEX NAME)

111224-39-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and oxidation of)
111224-39-6 CAPLUS
D-Kylitol, 3-deoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-1-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)-, (IR)- (9CI)
(CA INDEX NAME) IT

L4 ANSWER 28 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1987:618007 CAPLUS
107:218007
Anticancer nogalemycin analogs: 2,6-epoxy-3,4,5,6-tetrahydro-2R-naphthaleno[1,2-b]oxocin-9,12-dione derivatives
TINVENTOR(S):
Terajima, Atsuror Kawasaki, Motoshir Matsuda, Fuyuhikor Yamada, Kaoru
PATENT ASSIGNEE(S):
SOURCE:
JAPAN KOKAI TORKYO KOho, 14 pp.
COUDEN JKOKAF
DOCUMENT TYPE:
DOCUMENT TYPE:
LANGUAGE:
Japanese

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. DATE APPLICATION NO. JP 62153289 JP 06000784 PRIORITY APPLN. INFO.: 19870708 19940105 JP 1985-292242

The title compds. (I; R1 = H, protecting group), which show anticancer activity, are prepared in 9 steps from 3,5,6-trihydroxy-4-amino-2-hexanone derivative (II). Lithiation of 1,4,5,8-tetramethoxynaphthalene (III; R = H) with Bull followed by condensation with (R1 = SINE2CMe3) and desilylation with BulMP gave III (R = Q, R1 = SIME2CMe3). Oxidation of the latter with ClCCCCCl and Me2SO and reduction of the resulting III (R = Q1, R2, R3 = W, CMC, R3 = CH2CMe, R5 = CC2Me) with (iso-Bu)2AH in toluene at -78° gave III (R = Q1, R2, R3 = H, CM(R2 = R3), R4 = CH2CMe, R5 = CC2Me) with clCH2CMe in THF containing (iso-Pr)2NH and deacylated by reduction with LiALH4 to give III (R = Q1, R2, R3 = H, CMC2CMe (R2 = R3), R4 = CH2CMe, R5 = H). Treatment of the latter with (NH4)2Ce(NO3)6 in aqueous EtCH at 0° gave 5,8-dimethoxy-1,4-dioxonaphthalene derivative III (R = Q1, R2, R3 = H, CM2CMe, R5 = H). Which was reduced with Na2S2O4 in H2O and CHC13 and cyclized by treatment with BrSiMe3 in CHC13 and CH2C12 under reflux to

saeed

105827-48-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or resgent)
(preparation and oxidation of)
105827-48-3 CAPLUS
L-Glucitol, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA
INDEX NAME)

ANSWER 28 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) give I (RI = R2 = H) +HBr. Acetylation of this with Ac20 in MacH conts, KOAc gave I (RI = R2 = Ac). This in vitro showed IC50 of 0.10 µg/mL in mouse leukemia P388 cells.

111224-40-9P
RL: RCT (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of, with chloromethyl Me ether)

111224-40-9 CAPLUS
L-Glucose, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (SCI) (CA INDEX NAME)

105827-47-2P
REL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation of)
105827-47-2 CAPLUS
L-Glucitol, 3,-G-dideoxy-1-0-[{1,1-dimethylethyl}dimethylsilyl}-3-[(methoxycarbonyl]methylamino]-2,4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ANSWER 29 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Naphthol derivs. I [R1 = H, Me, Br, Cl, OH, OMe, OEt, Ph, S, SO, SO2, (un) substituted NE2, etc., R2, R3 = H, Me, Et, OMe, OEt; R4 = alkyl, alkenyl, alkynyl, etc.] are prepared as 5-lipoxygenase inhibitors. Thus, 1,1-trimethoxy-5-hexyne in dry THF was treated at -78 "tith Buli in hexane, followed by the addition of 1-benzyloxy-2-naphthaldehyde in THF, to give Me 7-(1-benzyloxy-2-naphthaldehyde in THF, to give Me 7-(1-benzyloxy-2-haphthyl)-7-heptynoate. This was treated with a mixture of BF3.Et2O, Et3SiH, and CH2Cl2 to give Me 7-(1-benzyloxy-2-haphthyl)-5-heptynoate, which, upon treatment with EtSH and BF3.Et2O gave I (R1 = R2 = R3 = H, R4 = CH2C.tplbond.CCH2CH2CH2CO2Me). 109381-76-2P
RL: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation); USES (Uses)

(preparation of, as lipoxygenase inhibitor)
10381-76-2 CAPLUS
1-Naphthalenol, 2-(3-aminopropyl)-, hydrochloride (9CI) (CA INDEX NAME)

G HC1

ACCESSION NUMBER:	1987:4	52007 CAPLU	s									
DOCUMENT NUMBER:	107:52007											
TITLE:	2-Subs	tituted-1-na	phthols as 5-lipogygenase inhibitors									
INVENTOR(S):	Batt.	att, Douglas Guy										
PATENT ASSIGNER(S):	1987:452007 CAPLUS 107:52007 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors Batt, Douglas Guy du Pont de Nemours, E. I., and Co., USA Eur. Pat. Appl., 87 pp. CODEN: EPXCHW Pateat Renoish											
SOURCE:	Bur. P	Eur. Pat. Appl., 87 pp.										
	CODEN:	EPXXDV		r .								
DOCUMENT TYPE:	Patent											
LANGUAGE:	Englis	ı h										
FAMILY ACC. NUM. COUNT:	1	1										
PATENT INFORMATION:												
PATENT NO.	KIND	DATE	AP	PLICATION NO.		DATE						
EP 201071	A2	19861112 19880810	EP	1986-106122		19860505						
EP 201071	A3	19880810										
	B1	19920304										
R: AT, BE, CH,	DE, FR	i, GB, IT, LI	, L	U, NL, SR								
US 4833164	A	19890523	US	1986-839912		19860319						
AT 73121	E	19920315	λT	1986-106122		19860505						
AU 8657186	A1	19861204	AU	1986-57186		19860506						
AU 606034	B2	19910131										
CA 1302417	A1	19920602	CA	1986-508534		19860506						
DX 8602112	Α	19861109	DK	1986-2112		19860507						
FI 8601903	A	19861109	FI	1986-1903		19860507						
FI 90974	В	19940114										
FI 90974	С	19940425										
NO 8601829	A	19861110	NO	1986-1829		19860507						
NO 164592	В	19900716										
NO 164592	С	19901024										
JP 61263943	A2	19861121	JP	1986-103246		19860507						
JP 2554322	B2	19961113										
HU 43551	A2	19871130	HU	1986-1892		19860507						
HU 194796	В	19880328										
ZA 8603425	A	19880127	ŻA	1986-3425		19860507						
SU 1600627	A3	19901015	SU	1986-4027419		19860507						
IL 78719	A1	19930513	ΙL	1986-78719		19860507						
ES 554763	A1	19880216	ES	1986-554763		19860508						
ES 557756	A1	19880416	ΪS	1987-557756		19870925						
SU 1750415	A3	19920723	SU	1988-4355565		19880422						
EP 201071 R: AT, BE, CH, US 4833164 AT 73121 AU 8657186 AU 605034 CA 1302417 DX 6602112 FI 8601003 FI 90974 NO 8601829 NO 164592 NO 164592 NO 164592 JP 61263943 JP 2554322 HU 43551 HU 194796 ZA 8603425 SU 1600627 IL 78719 ES 554763 ES 557756 SU 1750415 US 4985435 US 4985435 US 4985435 US 4985435 US 4985435 US 4985435 US 5026759 NO 9000651 NO 171106 NO 171106 NO 171106 DK 9200393 PRIORITY APPIN. INFO.:	A	19900306	US	1989-324533		19890316						
US 4985435	Α	19910115	US	1989-324534		19890316						
US 4985442	Α	19910115	US	1989-327717		19890323						
US 5026759	λ	19910625	US	1989-445776		19891204						
NO 9000651	A	19861110	NO	1990-651		19900209						
NO 171106	В	19921019										
NO 171106	C	19930127										
DK 9200393 PRIORITY APPLN. INFO.:	A	19920325	DK	1992-393		19920325						
PRIORITY APPLN. INFO.:			US	1985-731791	λ	19850508						
			US	1986-839912	A	19860319						
			EP	1986-106122	A	19860505						
			ИО	1992-393 1985-731791 1986-839912 1986-106122 1986-1829	A1	19860507						
			US	1989-324533	A3	19890316						
OTHER SOURCE(S):	CASREA	CT 107:52007										

L4 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

L4 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1987:18203 CAPLUS DOCUMENT NUMBER: 106:18203 DOCUMENT NUMBER: TITLE: 106:18203
Total syntheses of (+)-nogarene and
(+)-7,8-dihydronogarene
Kawasaki, Hotoji; Hatsuda, Fuyuhiko; Terashima, Shiro
Sagami Chen. Res. Cent., Sagamihara, 229, Japan
Tetrahedron Letters (1986), 27(19), 2145-8
CODEN: TELEAY; ISSN: 0040-4039
Journal
English
CASREACT 106:18203 AUTHOR (5): CORPORATE SOURCE: DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(S):

OTHER SOURCE(S):

Total syntheses of the title compds. (I, RRI = bond, R = RI = H), the simplest and novel nogelamycin congeners, were accomplished by elaborating the CDEF-ring system II from HeCOCH(OH2OHs)CH(NHCOZHs)CH(OH2OHs)CH2OSIM e2CH63 and subjecting to regioselective Diels-Alder reaction with the bistrimethylsilyk ketne acetal II. I and some intermediates have annitumor activity.
105827-47-2P

105827-47-2P
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
(preparation and desilylation of)
105827-47-2 CAPLUS
L-Glucitol, 3.6-dideoxy-1-0-[(1,1-dimethylethyl)dimethylsilyl]-3-[(methoxycarbonyl)methylamino]-2.4-bis-0-(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

ANSWER 30 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

105827-48-3F
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)
105827-48-3 CAPLUS
L-Glucitol, 3,6-dideoxy-3-[(methoxycarbonyl)methylamino]-2,4-bis-0(methoxymethyl)-5-C-(1,4,5,8-tetramethoxy-2-naphthalenyl)- (9CI) (CA
1NDEX NAME) IT

L4 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

L4 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1986:101941 CAPLUS DOCUMENT NUMBER: 104:101941 TITLE: Topological pharmacophores. Ne

AUTHOR (S): CORPORATE SOURCE:

104:101941
Topological pharmacophores. New methods and their application to a set of antimalarials. Part 2: Results from LOGANA
Franke, Rainer; Streich, V. Juergen
Inst. Drug Res., Ger. Acad. Sci., Berlin, 1136, Ger. Dean. Rep.
Quantitative Structure-Activity Relationships (1985), 4(2), 51-63
CODEN: QSARDI; ISSN: 0722-3676
JOURNAL SOURCE:

DOCUMENT TYPE:

DOCUMENT TYPE: Journal
LANGUAGE: Rogliph
AB The LOGANA procedure is applied to a set of 382 antimalarials as a test
case. Its principle consists in the stepwise combination of binary
descriptors characterizing the presence or absence of substructural
features into conjunctions using the logical operator "and" such that the
structural patterns described by these conjunctions are typical of the
class of high activity compds. Clear substructural patterns for
antimalarial activity are obtained which are consistent with corresponding
Hansoh equations taken from the literature.

[17] 69757-95-8 69760-06-1

שני הארים - שני מיים שני הארים שני

(uses) (antimalerial activity of, topol. anal. of, by computerized methods) 69757-95-5 CAPUS
9-Phenanthrenemethanol, α-[(dibutylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)

69760-06-1 CAPLUS 9-Phenanthrenemethanol, $\alpha-[(diheptylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)$

L4 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1986:33908 CAPLUS
DOCUMENT NUMBER: 104:33908
INVENTOR(S): Naphthalene derivatives
INVENTOR(S): Hashimoto, Kinjij Goto, Kyotor Tsuda, Yoshiaki
Otsuka Pharmaceutical Factory, Inc., Japan
Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JOCKAF
Patant

DOCUMENT TYPE:

Japanese

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO.

JP 60139646 JP 03014296 PRIORITY APPLN. INFO.: GI 19850724 19910226 JP 1983-248760 19831227 JP 1983-248760 19831227

DATE

Naphthalene derivs. (I: R = alkoxy: R1 = CO2H, NO2, carbamoy1, dialkylcarbamoy1, etc.), effective vasodilators, thromboxane A2 biosynthesis inhibitors, cardiotonics, etc. (no data), were prepared Thus, 20 mmol II and 0.3 mL piperidine were added to a solution of 40 mmol malonic acid in pyridine at 80-85° and refluxed 3 h to give 5 g I (R = HeO, 99724-04-05-79 99724-05-69 99724-05-69 99724-05-09 PSP24-05-09 PSP2 AB

IT

99724-08-0P
RL: SPN (Synthetic preparation), PREP (Preparation)
(preparation of)
99724-04-6 CAPLUS
2-Naphthelacepropanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-1,4,5,8-tetramethoxy-(9CI) (CA INDEX NAME)

99724-05-7 CAPLUS L-Alanine, N-[1-0x0-3-(1,4,5,8-tetramethoxy-2-naphthalenyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 32 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

99724-06-8 CAPLUS L-Proline, 1-[N-[1-oxo-3-(1,4,5,8-tetramethoxy-2-naphthaleny1]propy1]-L-alany1]- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

99724-08-0 CAPLUS
Naphthalene, 1,4,5,8-tetramethoxy-2-(2-nitroethyl)- (9CI) (CA INDEX NAME)

ANSWER 33 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN CMF C14 H16 N2 O

L4 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:560194 CAPLUS

DOCUMENT NUMBER: 103:160194

AUTHOR(S): HoCarthy, James R.; Wright, Donald L.; Schuster, Albert J.; Abdellah, Abdul H.; Shea, Philip J.; Eyster, Randy

CORPORATE SOURCE: Pharmacol. Dep., Merrell Dow Res. Inst., Indianapolis, IN, 46268, USA

JOURNAI of Medicinal Chemistry (1985), 28(11), 1721-7

DOCUMENT TYPE: LANGUAGE: English

LANGUAGE: OTHER SOURCE(S): GI English CASREACT 103:160194

N,N'-Dialkylarylamides (67 in all) were prepared and evaluated for antidepressant activity. Several of these were prepared from the corresponding nitriles by conversion into the amidate esters than aminolysis. Slight structural modifications caused marked changes in biol. activity and led to compds. as active as imipramine. The arylacetandidne I (napactadine) was selected for clin. study. 98245-94-4P 98245-95-59
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SFN (Synthetic preparation); TRU (Therapeutic use); BIO. (Biological study); PREF (Preparation); USES (USes) (preparation and antidepressant activity of) 98245-94-4 CAPLUS
2-Naphthaleneethanimidamide, 1-hydroxy-N,N'-dimethyl- (9CI) (CA INDEX NAME)

98245-95-5 CAPLUS
2-Maphthaleneethanimidamide, 1-hydroxy-N,N'-dimethyl-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 98245-94-4

L4 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:523196 CAPLUS
DOCUMENT NUMBER: 103:123196
1.4.5,8-Tetraalkowynaphthalene
Otsuka Pharmaceutical Factory, Inc., Japan
SOURCE: CODEN: JNOKAF
DOCUMENT TUDE.

DOCUMENT TYPE: Patent

Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. APPLICATION NO. KIND DATE DATE JP 60100542 JP 04049536 PRIORITY APPLN. INFO.: OTHER SOURCE(S): 19850604 19920811 JP 1983-209712 19831107 A2 B4 JP 1983-209712 CASREACT 103:123196 19831107

Title compds. I [R = alkowy; R1, R2 = OH, alkancyloxy, NR3R4; R3, R4 = H, alkyl. cycloalkyl, (un)substituted Ph, phenylalkyl] and their salts, useful as cardiovascular agents (no data), were prepared Thus, treating 2.4 g II (R = OMe, R6 = CHO) with 1 g NaCN gave 2 g II [R = OMe, R6 = CHO + OME 1 g NaCN gave 2 g II [R = OMe, R6 = CHOHOLEN], 310 mg of which was treated with 300 mg MeZCO in the presence of NaBH3CN to give 272 mg I (R = OMe, R1 = OH, R2 = NR3R4, R3 = H, R4 = CHMeZ).

98187-37-22

RL: RCT (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reductive alkylation of)

98187-37-2 CAPUS

2-Naphthalenemethanol, c-(aminomethyl)-1,4,5,8-tetramethoxy- (9CI) (CA INDEX NAME)

98186-93-7P 98186-95-9P 98186-96-0P 98186-98-2P 98186-99-3P 98187-00-9P

ANSWER 34 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN 98187-38-39
RL: SPN (Synthetic preparation), PREP (Preparation) (prepn. of) 98186-93-7 CAPLUS

2-Naphthalenemethanol, 1,4,5,8-tetremethoxy-α-[[(2-phenylethyl)amino]methyl]- (9CI) (CA INDEX NAME)

98196-95-9 CAPLUS 2-Maphthalenemethanol, α -[(cyclohexylmethylamino)methyl]-1,4,5,8-tetramethoxy-(9C1) (CA INDEX NAME)

98186-96-0 CAPLUS
2-Naphthalenemethanol, α -[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-1,4,5,8-tetramethoxy- (9CI) (CA INDEX NAME)

98186-98-2 CAPLUS 2-Naphthalenemethanol, α -{(cyclohexylmethylamino)methyl]-1,4,5,8-tetramethoxy-, acetate (ester) (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) L4 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

98186-99-3 CAPLUS 2-Naphthalenemethanol, α -[(disthylamino)methyl]-1,4,5,8-tetramethoxy-, acetate (ester) (9CI) (CA INDEX NAME)

98187-00-9 CAPLUS 2-Naphthalenemethanol, 1,4,5,8-tetramethoxy-α-[(phenylamino)methyl]-(9CI) (CA INDEX NAME)

98187-38-3 CAPLUS 2-Naphthalenemethanol, 1,4,5,8-tetramethoxy- α -{{(1-methylethyl)amino]methyl}- {9CI} (CA INDEX NAME)

L4 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1984:486235 CAPLUS DOCUMENT NUMBER: 101:86235

DOCUMENT NUMBER: TITLE:

101:86235 Derivatives of 2-methyl-1,4-naphthoquinone as substrates and inhibitors of the vitamin K-dependent

AUTHOR (S):

CORPORATE SOURCE:

Subservates and inhibitors of the vitamin k-dependent carboxylase
Dhaon, Madhup K.; Lehrman, S. R.; Rich, D. H.;
Engelke, J. A.; Suttie, J. W.
Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI,
53706, USA
Journal of Medicinal Chemistry (1984), 27(9), 1196-201
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE:

CODEN: JMCMAR: ISSN: 0022-2623

UMENT TYPE: Journal
GUAGE: English
A series of peptides that contain an N-terminal 2-methyl-1,4naphthoquinone group or analogs of this structure were prepared as potential
substrates or inhibitors of the rat liver microsomal vitamin K-dependent
carboxylase. The parent compound, y-2-(methyl-1,4-naphthoquinonyl3] butyryl-clu-Glu-Leu-CWe, was a good substrate for the carboxylase at low
concess, and had a Kn of .apprx.50 µM. This was roughly 2 orders of
magnitude lower than the Km of most simple peptide substrates that were
synthesized. Replacement of the 2-methyl-1,4-naphthoquinone group with
its demethyl analog, a naphthyl, or a stearyl group decreased substrate
effectiveness. At higher concens, the parent compound and its demethyl
analog were potent inhibitors of the vitamin K-dependent carboxylation
reaction. The degree of inhibition exhibited by these peptides was
dependent on the vitamin KH2 concentration of the incubation.

82376-03-08P
RLI RCT (Reactant), SPN (Synthetic preparation). PARE (**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Meactant or reagent)
(Preparation and hydrogenolysis of)
82376-83-8 CAPLUS
L-Leucine, N-[N-[4-(1,4-dimethoxy-3-methyl-2-naphthalenyl]-1-oxobutyl]L-a-qlutamyl]-1-a-glutamyl]-, 1-methyl 5,5'-bis(phenylmethyl)
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

82376-85-0P

RELIFICATION (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent) (Reactant or reagent) (preparation and reaction with vitamin K-dependent carboxylase) 82376-85-0 CAPUS
L-Laucine, N-[N-[N-[4-(1,4-dimethoxy-3-methyl-2-naphthalenyl)-1-oxobutyl]-L-a-glutamyl]-L-a-glutamyl]-, 1-methyl ester (SCI) (CA INDEX

ANSWER 35 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN NAME)

Absolute stereochemistry.

ANSWER 36 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) Adenosine, N-[3-(1,4-dimethoxy-3-methyl-2-naphthalenyl)propyl]- (9CI) (CA INDEX NAME)

87541-31-9F
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
87541-31-9 CAPLUS
Naphthalene, 2-(3-azidopropyl)-1,4-dimethoxy-3-methyl- (9CI) (CA INDEX

L4 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1983:576222 CAPLUS
DOCUMENT NUMBER: 1983:576222 CAPLUS
TITLE: Quinone derivs
Takeda Chemical Industries, Ltd., Japan
Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JECKAF
DOCUMENT TYPE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE JP 58083698 JP 01033114 PRIORITY APPLM. INFO.: OTHER SOURCE(S): GI 19830519 19890711 JP 1981-182725 19811113

JP 1981-182725 CASREACT 99:176222

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The title compds. I (R = Me, MeO, etc.) X = CH:CH, C.tplbond.C, m = 0-3; n = 1-20; p = 1-5; q = 0-3) were prepared by deprotection of the hydroquinone derivs. II (R1 = protecting group). Thus, 4.11 g Ce(IV) NH4 nitrate in MeCN was added to a mixture of 2.5 mH II (R = HeO, R1 = He, m = q = 0, n = 1), 1.25 g 2,6-pyridinedicarboxylic acid oxide, 10 mL MeCN, and 5 mL H20 with ice cooling over 20 min and the resulting mixture stirred at the same temperature for 20 min to give I (R = MeO, m = q = 0, n = 1) (no yield n).

19811113

given).

In vivo and in vitro data for the antihypertensive, and antileukemia, and coronary vasodilating activities of I are given.

IT 87541-56-89

87541-56-89
RL: SPN (Synthetic preparation), PREP (Preparation)
(preparation and condensation with chlororibofuranosylpurine)
87541-56-8 CAPLUS
2-Naphthalenepropanamine, 1,4-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)

ΙT 87541-77-39 RE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and oxidative demethylation of) 87541-77-3 CAPLUS

L4 ANSWER 37 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1983:575333 CAPLUS
99:175333
Synthesis and molecular-crystalline structure of
2-phenyl-3-[1-hydroxy-2-(N-methylanilino)ethyl]-1,4naphthoquinone
Hishnev, A. F.; Bleidelis, J.; Larina, L.; Lokmane,
E.; Freimanis, J.
CORPORATE SOURCE:
1net. Org. Sint., Riga, USSR
Zhurnal Organicheskoi Khimii (1983), 19(6), 1289-93
CODEN: ZORKAR; ISSN: 0514-7492
JOURNAL ANGUAGE:
RUSSIAN

DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(5): GI Russian CASREACT 99:175333

AB Reduction of naphthoquinone I (2 = CO) with NaBH4 in EtCH gave naphthalenediol derivative II, which was oxidized by bubbling air through the reaction

derivative II, which was objected by according to give 60.1% title compound, I [Z = CH(OH)]. The x-ray crystal and mol. structure of the latter indicated an intramol. H bond involving the OH group and the adjacent CiO group, increasing the overall planarity of the mol. The increased coplanarity of its donor and acceptor fragments altered the crystal packing and hindered intermol. donor-acceptor

interactions. 87537-31-39

67537-31-3P
RE: RCT (Reactant), PREP (Preparation), RACT (Reactant or reagent)
 (formation and oxidation of)
87537-31-3 CAPUUS
1,4-Naphthalenediol, 2-[1-hydroxy-2-(methylphenylamino)ethyl]-3-phenyl(9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1982:439370 CAPLUS
DOCUMENT NUMBER: 97:39370

Synthesis of naphthoquinone tripeptide which inhibits vitamin X-dependent carboxylase
Lehrman, S. R.; Rich, D. H.; Goodman, H. L.; Suttie, J. V.
CORPORATE SOURCE: Sch. Pherm., Univ. Visconsin, Madison, WI, 53706, USA Pept.: Synth, Struct., Funct., Proc. Am. Pept. Symp., 7th (1981), 513-16. Editor(s): Rich, Daniel H.; Gross, Erhard. Pierce Chem. Co.: Rockford, 111.
CODEN: 471MAO
CONFERNIT TYPE:
LANGUAGE: English

DOCUMENT TYPE: LANGUAGE: GI

(CH₂) 3CO-Glu (OR) - Glu (OR) - Leu-OHe (CH₂) 3CO-Glu (OR²) -Glu (OR²) -Leu-OMe

Title tripeptide I (R = H) (II) was prepared from H-Glu(OCH2Ph)-Glu(OCH2Ph)-Leu-OHe.HCl (III) and naphthalenes IV or V. IV was condensed with III by DCC/1-hydroxybenzotriezole (HOBt) in CH2Cl2 containing Rt3N to give 304 I

CH2Ph), which underwent hydrogenolysis over Pd/C to give tripeptide VI (R1 = R2 = H), which was oxidized by air to give >98% II. A 2nd route involved condensing V with III by DCC/HOBt in CH2Cl2 containing Et3N to give 75% VI (R1 = Me, R2 = CH2Ph), which was dehenzylated by hydrogenolysis over Pd/C to give >98% VI (R1 = Me, R2 = H), which was demethylated by AgO/HNO3 to give 50% II. II and VI (R1 = H, He; R2 = H) were assayed as sybstrates for the title enzyme; II was carboxylated to the same extent as a standard peptide, whereas IV (R1 = Me, R2 = H), was a poor substrate.

ANSWER 38 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN NAME)

Absolute stereochemistry.

ANSWER 38 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
e2376-e3-e8
RL: RCT (Reactant), SFN (Synthetic preparation), PREP (Preparation), RACT
(Reactant or reagent)
(preparation and hydrogenolysis of)
82376-e35 - CAPLUS
L-Leucine, N-(N-[N-[4-(1,4-dimethoxy-3-methyl-2-naphthalenyl)-1-o-sobutyl]-L-e-glutamyl]-, 1-methyl 5,5'-bis(phenylmethyl)
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

82376-84-9P 82376-85-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and oxidation and vitamin K dependent carboxylase substrate

activity of) 82376-84-9 CAPLUS

L-Leucine, N-[N-[N-[4-(1,4-dihydroxy-3-methyl-2-naphthalenyl]-1-oxobutyl]-L-a-glutamyl]-L-a-glutamyl]-, 1-methyl ester (9CI) (CA INDEX

Absolute stereochemistry.

82376-85-0 CAPLUS
L-Laucine, N-IM-[N-[4-(1,4-dimethoxy-3-methyl-2-naphthalenyl)-1-oxobutyl]L-a-glutamyl]-L-a-glutamyl]-, 1-methyl ester (SCI) (CA INDEX

L4 ANSWER 39 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1980:446298 CAPLUS
COFFECTION of: 1979;575112
S146299 CAPLUS
COFFECTION of: 1979;575112

TITLE:
Heterocyclic spiro-naphthalenones. Part III.
Synthesis and reactions of some spiro[naphthalene-1,2'-pyrrolidin]-2-ones and spiro[naphthalene-2,2'-pyrrolidin]-1-ones
Berney, Daniel; Schuh, Karlheinz
CORPORATE SOURCE:
SOURCE:
DOCUMENT TYPE:
DOCUMENT TYPE:
JURIAN JURIAN ACCALVY, ISSN: 0018-019X
JOURNAL

DOCUMENT TYPE: Journal English CASREACT 93:46298

LANGUAGE: OTHER SOURCE(S): GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Spironaphthalenepyrrolidinones I (R = H, RI = He, X = H2) R = Ph, RI = CH2Ph, X = H2; R = Ph, RI = Me, X = O) were obtained by treating II with N-bronosuccinimide. III similarly gave a mixture of cis- and trans-IV. NaBH4 reduction of cis-IV gave only the α-ol, whereas trans-IV gave a mixture of the α- and β-ols. The alcs. were reduced to tetrahydronaphthols, which rearranged on treatment with polyphosphoric acid to the benzofluorenopyrrole V.
71593-46-IP
RL: RCT (Reactant), SPN (Synthetic pranaration), DDEP (Parametrical)

RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT

(Meactant or reagent)
(preparation and cyclization of, spironaphthalenepyrrolidinone from)
71593-48-1 CAPLUS
1-Naphthalenol, 2-[3-(methylamino)-1-phenylpropyl]- (9CI) (CA INDEX NAME)

71593-47-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reduction of)
71593-47-0 CAPLUS
2-Maphthalenepropanamide, 1-hydroxy-N-methyl-β-phenyl- (9CI) (CA INDEX NAME)

ANSWER 39 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ANSWER 40 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

L4 ANSWER 40 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1979:575112 CAPLUS
91:175112
Heterocyclic spiro-naphthalenones. Part III.
Synthesis and reactions of some spiro[naphthalene-1,2'-pyrrolidin]-2-ones and spiro[naphthalene-2,2'-pyrrolidin]-1-ones
Berney, Danlel: Schuh, Karlheinz
Vander Res. Inst., Bern, CH-3001, Switz.
Helvetica Chinica Acta (1979), 62(4), 1268-74
CODEN: HCACAV, ISSN: 0018-019X
JOURNEL LANGUAGE:
GI

DOCUMENT TYPE: LANGUAGE: GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Spironaphthalenepyrrolidinones I (R - H, Rl - Me, X - H2, R - Ph, Rl - CH2Ph, X - H2, R - Ph, Rl - Me, X - O) were obtained by treating II with N-bromosucciniaide. III similarly gave a mixture of the and trans-IV. NamHd reduction of cis-IV gave only the e-ol, whereas trans-IV gave a mixture of the e-and P-ols. The alcs. were reduced to tetrahydronaphthols, which rearranged on treatment with polyphosphoric acid to the benzofluorencypyrole V. 71893-48-19
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent) (preparation and cyclization of) 71593-48-1 CAPLUS
1-Naphthalenol, 2-[3-(methylamino)-1-phenylpropyl] - (9CI) (CA INDEX NAME)

71593-47-OP
RL: RCT (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
71593-47-O CAPUS
2-Maphthalenepropanamide, 1-hydroxy-N-methyl-β-phenyl- (9CI) (CA IT

L4 ANSWER 41 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1979:161936 CAPLUS
90:161936
Quantitative structure-activity relationships in
1-aryl-2-(alkylamino) ethanol antimalarials
XLIM, K. Hwan, Hansch, Corvin, Fukunaga, James Y.,
Steller, Edward E., Jow, Priscilla Y. C., Craig, Paul
N., Page, June
Dep. Chen., Fomona Coll., Claremont, CA, USA
Journal of Medicinal Chemistry (1979), 22(4), 366-91
CODEN: JNCMAR, ISSN: 0022-2623

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

AB A quant. structure-activity relation (QSAR) was formulated for 646

arylcarbinol antimalarials (X-ArCHOMCHZMRIR2, having 60 different

structures including heterocycles) against Plasmodium berghei, using a

equation having 14 terms, 9 of which are indicator variables. The most
important determinate of activity was the electron-withdrawing ability of

X, whereas the hydrophobic nature of both X and R was less important. The

correlation coefficient and the standard deviation for the QSAR were 0.898

and

0.309, resp. An addn1 number of compds. were investigated and the lack of activity of .apprx.100 analogs are discussed.

52878-74-2 69735-87-2 69737-07-9
69757-10-0 69737-18-2 69737-95-5-5
69760-06-1
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(antimalarial, parameters for predicting activity of)
52978-74-2 CARUS
9-Phenanthrenemethanol, a-{(dibutylamino)methyl}-10-phenoxy- (9CI) (CA INDEX NAME)

69756-87-2 CAPLUS 9-Phenanthrenemethanol, 2,7-dibromo- α -[(dibutylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)

(Continued)

ANSWER 41 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued 69757-07-9 CAPLUS 9-Phenanthrenemethanol, 2,7-dichloro-a-[(dibutylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)

69757-16-0 CAPLUS

9-Phenanthrenemethanol, 2,7-dibromo-α-{(diheptylamino)methyl}-10-methoxy- (9CI) (CA INDEX NAME)

RN CN

69757-18-2 CAPLUS 9-Phenanthrenemethanol, 2,7-dichloro-α-[(diheptylamino)methyl]-10-methoxy- (9C1) (CA INDEX NAME)

69757-95-5 CAPLUS 9-Phenanthrenemethanol, α -[(dibutylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1978:563295 CAPLUS
DOCUMENT NUMBER: 89:163295

TITLE:

89:163295
Photochemical reactions of aromatic compounds. XXXII.
A Michael-type alkylation of the naphthalene ring
utilizing regiospecific photocycloaddition
Pac, Chyongjinr Mizuno, Kazuhiko; Okamoto, Hisanori;
Sakurai, Hiroshi
Inst. Sci. Ind. Res., Osaka Univ., Suita, Japan
Synthesis (1978), (8), 589-90
CODEN: SYNTEF; ISSN: 0039-7881
Journal

11

AUTHOR (S):

CORPORATE SOURCE: SOURCE:

DOCUMENT TYPE: Journal English CASREACT 89:163295

LANGUAGE: OTHER SOURCE(S): GI

2-Alkylated naphthalenes I (R = H, Rl = H, Me; R = Et, Rl = H) and II (R2 = H, R3 = CO2Et, R4 = H, He; R2 = Me, R3 = CN, R4 = H) were prepared by irradiation of benzene solns. of 1-cyano- or 1-(trimethylsiloxy) naphthalene and silyl enol ethers RCH:CRIOSIME3 or acrylic acid derivs. R2CH:CR3R4, resp., followed by hydrolysis. 67858-29-18.

RL: SFN (Synthetic preparation); PREP (Preparation)

(preparation of)
67858-29-1 CAPLUS
2-Naphthaleneacetamide, 1-methoxy-a-methyl-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

69760-06-1 CAPLUS 9-Phenanthrenemethanol, α-[(diheptylamino)methyl]-10-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1974:563214 CAPLUS
DOCUMENT NUMBER: 81:163214
TITLE: Potential antimalarials. 8. 10-Substituted

AUTHOR (S)

CORPORATE SOURCE: SOURCE:

DOCUMENT TYPE: LANGUAGE:

TUMENT NUMBER:

CLE:

Potential antimalarials. 8. 10-Substituted
9-phenanthrenemethanols
Washburn, Lee C., Pearson, D. E.
Dep. Chem., Vanderbilt Univ., Nashville, TN, USA
Journal of Medicinal Chemistry (1974), 17(7), 676-82
COEMI JOURNT TYPE:

GUAGE:

Of a series of 14 title compds. prepared and tested for antimalarial
activity by the Rane Plasmodium berghei test in mice, 2,7-dibromo-9-(2dibutylamino-1-hydroxyethyl)-10-methylphenanthrene-HCl (1) [52579-66-5]
was most active, giving 4/5 cures at 80 mg/kg. I was prepared from
2,7-dibromo-9-methoxyphenanthrene [16430-42-5] by bromination in the 10
position, butyllithium exchange selectively at the 10 position, and
treatment with DMF to give the aldehyde, which gave the desired product in
a 2-step procedure via the epoxide. I at 40 mg/kg gave twice the survival
as 6-bromo-9-(2-diheptylamino-1-hydroxyethyl)phenanthrene-HCl [23257-53-6]
(May compound). Structure-activity relations and applications of the
reactions to other syntheses were discussed.
32279-36-30 \$2379-36-39 \$2379-36-74 \$2379-36-76*
\$2279-81-4P \$2379-86-9P \$4966-69-7P
RL: BAC (Biological activity or effector, except adverse), BSU (Biological
study, unclassified), SPN (Synthetic preparation), THU (Therapeutic use),
[Dreparation and antimalarial activity of)
\$279-56-51 CAPLUS
9-Phenanthrenemethanol, 2,7-dichloro-a-[(dibutylamino)methyl]-10methoxy-hydrochloride (961) (CA 1NDRENAME)

9-Phenanthrenemethanol, 2,7-dichloro-α-[(dibutylamino)methyl]-10-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

52979-57-4 CAPLUS
9-Phenanthrenemethanol, 2,7-dichloro-α-[(diheptylamino)methyl]-10-methoxy-, hydrochloride (9C1) (CA INDEX NAME)

ANSWER 43 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

• HC1

52979-67-6 CAPLUS
9-Phenanthrenemethanol, 2,7-dibromo-α-[(diheptylamino)methyl]-10-methoxy-, hydrochloride (9C1) (CA INDEX NAME)

• HC1

52979-81-4 CAPLUS 9-Phenanthrenemethanol, α -[(dibutylamino)methyl]-10-methoxy-, hydrochloride (9Cl) (CA INDEX NAME)

● HCl

L4 ANSWER 44 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
FAILLY ACC. NUM. COUNT:
PATENT NORPHATION:
FAMILY ACC. NUM. COUNT:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
***************************************				-	
GB 1347871	Α	19740227	GB 1971-10458		19710421
PRIORITY APPLN. INFO.:			GB 1971~10458	Α	19710421
AT T. 1/ / 1					

un 14 *8'11

A 19740227 GB 1971-10458 19710421

RORITY APPLAI INFO.:

For diagram(s), see printed CA Issue.

Forty-two title compds. (In n = 1, 2; m = 0, 1; R = H, alkoxy; R1 = substituted and unsubstituted phenyl, 2-thienyl, 2-furyl, and naphthyl; R2 = H, He, Et; R3 = H, Me, Et; R4. Ctplbond.C) and/or their hydrochlorides were prepared by Mannich reaction of appropriate 1-aminoadmantanes, HCHO, and RICOCHER2 to give ketone (II) and subsequent treatment of II with RACCHEN-CHEZ) mHyGl. Thus, 1-aminoadmantanes hydrochloride, PhcOMe, and 37% aqueous HCHO acidified with concentrated Hcl were refluxed 4 hr to II.HCl (R1 = Ph, R2 = R3 = H, II ts free base in Et2O was treated with PhCH2MgCl to give I.HCl (m = I, R = R2 = R3 = H, R1 = Ph). The results of pharmacodynamic tests were given.

S2955-30-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) 52955-30-3 CAPUS
2-Naphthalenemethanol, 1-methoxy-a-[2-(methyltricyclo[3.3.1.13,7)decl-1-ylamino)ethyl]-a-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

■ HC1

ANSWER 43 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Contin 52979-86-9 CAPLUS 9-Phenanthrenemethanol, a-[(diheptylamino)methyl]-10-methoxy-, hydrochloride (9C1) (CA INDEX RAME) (Continued)

• HC1

54966-69-7 CAPLUS 9-Phenanthrenemethanol, α-[(dibutylamino)methyl]-10-phenoxy-, hydrochloride (9CI) (CA INDEX NAME)

● HC1

L4 ANSWER 45 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
AUTHOR(S):
CORPORATE SOURCE:
SOURCE:
DOCUMENT TYPE:

CAPLUS COPPRIGHT 2005 ACS on STN
1972:539660 CAPLUS
77:139660
Synthesis of (heterocyclicamino) aminoalkylnaphthols and reduced tetrahydro derivatives for possible antimalarial activity
Nabih, I./ Nasr, H./ Badawi, M. A.
Natl. Res. Centr., Cairo, Egypt
Journal of Pharmaceutical Sciences (1972), 61(9),
1500-2
CODEN: JPMSAE; ISSN: 0022-3549
Journal

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB 1-Maphthols I (R - NEt2, piperidino; R1 = NH2, NO2, 7-chloro-4quinolylamino, 6-chloro-2-methoxy-9-acridylamino) and the corresponding
tetrahydronaphthols II were prepared E.g., treatment of 4-nitro-1-naphthol
and Et2NH in absolute EtCH with 378 H2CO gave I (R - NEt2, R1 = NO2).

Reaction of II (CH2R - H, R1 = NHAe), with Et2NH and paraformaldehyde in
absolute EtCH gave II (R - NEt2, R1 = NHAc).

II 37796-63-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dichloroquinoline and dichloromethoxyacridine)

RN 37796-63-7 CAPLUS

CN 1-Maphthalenol, 4-amino-2-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 55
ACCESSION NUMBER:
DOCUMENT NUMBER:
1969:47149 CAPLUS
70:47149 Synthesis of 2-methyl-3-vinyl-1,4-naphthoquinones
80 AUTHOR(S):
80 AUTHOR(S

MENT TYPE: Journal WAGE: Anglish For diagram(s), see printed CA Issue. Chlorobiumquinone [1a], previously isolated from Chlorobium thiosulfatophilum and characterized as a 2-methyl-3-vinylmultiprenyl-1,4-maphthoquinone, is unique among natural multiprenylquinones to being a vinyl- rather than an allylquinone. Various approaches to the synthesis of 2-methyl-3-vinyl-1,4-maphthoquinone (I) derivs. were studied, and two general syntheses developed, both constructing the substituted vinyl side chain via the Wittig reaction. A primary requirement for both methods was a protecting protocol for the 1,4-0 functions which would be inert to the ylide yet would allow generation of the quinone without destruction of the vinyl group. Such functionality was provided by the 1-pivalate ester-4-Me ether. These groups do not react with the ylide, and removal of the ester with LiAlH4 and oxidation of the 1-hydroxy-4-methoxy compound with FeCl3

quinone while leaving the vinyl side chain intact. One synthesis proceeded via 3-chloromethyl-4-methoxy-2-methyl-1-naphthyl pivalate which was converted into its tri-phenylphosphonium salt and thence to vinyl derivative by generation of the naphthalenic ylide and reaction with a carbonyl component. The other synthesis utilized the 3-naphthaldehyde, prepared from the chloromethyl compound and K 2-propanenitronate, in tion

tion with the appropriate ylide. To avoid isomers, some secondary ylides were prepared by alkylation of primary ylides. The relative advantages and disadvantages of both methods are considered. The separate, isomeric, vinyl compds, were obtained, and cis and trans stereochem, assignments made by relating their N.M.R. absorptions to those of unambiguous synthetic models. Various vinyl substitution patterns can be easily distinguished from the uv absorption of the resulting I derivs. 47 references.

17827-38-2P 17827-57-5P

IT

17827-38-2F 17827-37-5F
RE: SPN (Synthetic preparation); PREF (Preparation)
(preparation of)
17827-38-2 CAPLUS
2-Naphthaleneethylamine, 1,4-dimethoxy-3-methyl-, hydrochloride (8CI) (CA
INDEX NAME)

L4 ANSWER 47 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1966:103968 CAPLUS COUNTENT NUMBER: 64:103968 CAPLUS CORGINAL REFERENCE NO.: 64:19518h,19519a-b

β-Adrenergic blocking medicaments Imperial Chemical Industries Ltd. 19 pp. Patent TITLE: PATENT ASSIGNEE(S):

SOURCE: DOCUMENT TYPE:

Unavailable

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

FR M3564

PRIORITY APPLN. INFO::

GB 19620117

For diagram(s), see printed CA Issue.

B Compns. containing compds. of the general formula I have β-adrenergic blocking activity and are useful in the treatment of coronary arterial disorders. The compns. may be in the form of tablets and capsules

containing $^{5-500}$ mg. I. The preparation of compns. is described containing I (R and NR'R')

given): H, EtNH; H, PrNH; H, cyclohexylamino; Me, NH2; H, PhCH2CH2NH; H, BuNH; H, iso-PrNH; H, iso-Pr2N (II); H, piperidino; H, Me2N. To a stirred solution of 10 parts 2-bromoacetylnaphthalene in 10 parts MeOH was rapidly added 3 parts NaBH4 at <25° and, after 30 min. at 20°, pouring into ice and extracting with Et2O gave crude 1-(2-naphthyl)-2-bromoethanol (III). Heating 6.3 parts III and 8 parts iso-Pr2NH in 16 parts StOH under reflux 16 hrs. gave after evaporation, conversion to the hydrochloride, and chromatography of the base on Al2O3, II.HCl, m. 160-1° (MeOH-AcOEt).

6047-54-7, 2-Naphthalenemethanol, a-(1-aminoethyl)-1-methoxy-(preparation of 10)

IT

(preparation of 6047-54-7 CAPLUS of)

2-Naphthalenemethanol, α-(1-aminoethyl)-1-methoxy- (7CI, 8CI) (CA INDEX NAME)

ANSWER 46 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

● HC1

17827-57-5 CAPLUS Ammonium, (2-(1,4-dimethoxy-3-methyl-2-naphthyl)ethyl]trimethyl-, iodide (6C1) (CA INDEX NAME)

L4 ANSWER 48 OF 55 CAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 1966:103967 CAPLUS
OCCUMENT NUMBER: 64:103967
ORIGINAL REFERENCE NO.: 64:19518e-h

TITLE: N-(1-Naphthylmethyl) guanidine and acid addition salts thereof

Dvornik, Dusan American Home Products Corp. INVENTOR(S): PATENT ASSIGNEE(S):

SOURCE: DOCUMENT TYPE: 2 pp. Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE US 3248426 19660426 us 19620301 US 3248426 I9600426 US 19620301 The title compds. were prepared by converting the NHZ group in 1-naphthylmethylamine (I) to a guanidino group and treating the free compound with a halogen acid. Thus, an emulsion of 16.8 g. I and 23.4 g. S-methylisothiuronium iodide in 50 ml. H2O was stirred under reflux and N 6.5 hrs., cooled, and filtered to give 20 g. iodide salt. The salt was dissolved in 100 ml. hot H2O, the solution made strongly alkaline with

oily base formed extracted with CHCl3, the CHCl3 extract dried (Na2SO4),

treated with dry HCl to give an oily chloride salt which crystallized spontaneously on addition of EtOAc to give N-(1-naphthylmethyl) quanidinium iodide [II] (R = Rl = H, X = I) [III], m. 197-200' (MeoN-EtOAc). To a solution of 7 g. I, 80 ml. BuoH and 44.5 millimoles 1-quanyl-3,5-dimethylpyrazole nitrate was added, the mixture refluxed 2 hrs. under N and cooled, the crystalline product produced dissolved in MeOH and treated with

to give 8 g. nitrate salt (IV), m. $154-60^\circ$. IV was dissolved in MeOH, made strongly alkaline with NaOH, the separated oily base dissolved

and acidified with gaseous HCl, and the resultant solution evaporated to dryness

ess in vacuo. The residue was taken up in Me2CO and the Me2CO solution treated with Et2O to give III, m. 198° (Me0H-EtcAc). Also prepared were the following II (R, R1, X, and m.p. given): Me, H, II, 189-90° (Me0H-EtcAc); Me, H, Cl, 210-11° (Me2CO-Et2O); Bu, H, picrate, 127-8° (iso-PrOH-Et2O); Me, H, I, 209-11° (ME2CO-Et2O); These compds. have hypotensive properties which are due to peripheral sympathetic blockade; they also have good intestinal absorption after oral administration, a property especially desirable in the treatment of chronic hypertension.

6047-54-7, 2-Naphthalenemethanol, a-(1-aminoethyl)-1-methoxy-(preparation off)

ΙT

(preparation of)
6047-54-7 CAPLUS
2-Naphthalenemethanol, \(\alpha \) (1-aminoethyl) -1-methoxy- (7CI, 8CI) (CA

ANSWER 48 OF 55 CAPLUS COPYRIGHT 2005 ACS OR STN (Continued)

L4 ANSWER 50 OF 55 C ACCESSION NUMBER: DOCUMENT NUMBER: DOCUMENT NUMBER: TITLE: INVENTOR(5): PATENT ASSIGNEE(5): SOURCE: DOCUMENT TYPE: LANGUAGE: CAPLUS COPYRIGHT 2005 ACS on STN 1964:60720 CAPLUS 60:60720 D.: 60:10621f-g Naphthols Gac, Robert, Zeppieri, Louis Frogil 21 pp. Patent Unavailable LANGUAGE: PATENT INFORMATION:

PATENT NO. DATE DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

FR 1344298 19631129 FR 19620830
GB 103147

AB Tetralones and tetralols were heated at .apprx. their b.p. at 1-5
atmospheric in
the presence of a dehydrogenation catalyst such as Ni, Cu, Fe, Co, Cr, or
Ft on a CaO, MgO, CuO, SrO, or ZoO support to give the title compds.

(apparatus)
pictured). Thus, 1 part CuO was mixed with 2 parts ZnO, cylindrical
pellets (3 + 3 mm.) were prepared from the mixture, and the pellets
reduced in H at 100-275 to give a catalyst containing metallic Cu.
The prepared catalyst (1000 g.) was placed in a reactor at 200°, 1700
g. tetralone preheated at 200°, and the tetralone passed over the
catalyst bed at 10 m./hr. 10 hrs. to give a product containing 22.1%
--naphthol and no tetrahydronaphthol.

IT 6047-86-7, 2-Naphthalenemethanol, α-(1-aminoethyl)-1-methoxy(pharmaceutical containing)

RN 6047-54-7 CAPLUS
CN 2-Naphthalenemethanol, α-(1-aminoethyl)-1-methoxy(TCI, 8CI) (CA
INDEX NAME)

L4 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1965:82334 CAPLUS 1905:82334 CAPWS
62:82333, 14553a-1
62:16532h, 14553a-1
62:1652h, 14554a-1
62:1652h, 14554a-1
62:1652h, 14554a-1
62:1652h, 14554a-1
62:1652h, 14554a-1
62:1652h, 14554a-1
62:1652h, 1455 DOCUMENT NUMBER: ORIGINAL REFERENCE NO.: TITLE: anhydride Sarel, Shalom, Breuer, Eli Hebrew Univ. School Pharm., Jerusalem Chemistry & Industry (London, United Kingdom) (1965), (11), 467 CODEN: CHINAG, ISSN: 0009-3068 CORPORATE SOURCE: SOURCE: COMEN: CHINNAG ISSN: 0009-3068

COMEN: CHINNAG ISSN: 0009-3068

COMEN: CHINNAG ISSN: 0009-3068

COMEN: CA 54, 17299e. The title product (I) was shown to be a feeplish

Cf. CA 54, 17299e. The title product (I) was shown to be a feeplish control of the chemical analysis, its uv spectrum with peaks at 230 mm (e 53,000) (the extinction volue given for the lat maximum (loc. cit.) is wrong), 277 mm (e 6600), and ir spectrum with peaks at 230 mm (e 53,000) (the extinction volue given for the lat maximum (loc. cit.) is wrong), 277 mm (e 6600), and ir spectrum with the carbonyl band at 1818 cm. 1 The structure was also confirmed by the synthesis: by alkaline hydrolysis followed by neutralization, of the hydroxy acid (IIs), in 144-5', 82tct 234 mm (41000), 281 mm (4100), ARBr 1724 cm. -1 (carbonyl); by mathanolysis of the hydroxy ester (IIb), m. 125-6' ARBr 1733 cm. -1 (ester carbonyl); and by ammonolysis of the hydroxy maximum (115), and 150 cm. -1 (amide carbonyl). Short heating of IIs, IIb, or IIc above the mm. respensable of the hydroxy ester (III), m. 163-4', which showed no teadency to form I on heating, and which, unlike IIs, IIb, and IIc, gave no color with Fecl3 in 810H solution The N.H.R. spectrum of 1 showed multiplets between 0.5-0.8 ppm. (2 protons), and at 1.5-2.2 ppm. (1 proton) which are characteristic of cyclopropyl H atoms; a doublet centered at 3.8 ppm. (2 protons) assigned to the H atoms at to the carbonyl; and a singlet at 7.22 ppm. (1 proton) assigned to Hl. The multiplets seen at the lower field between 7.30-7.35 ppm. represent H3, H4, H5, H6.
2089-71-6, 2-Naphthaleneacetamide, 4-cyclopropyl-1-hydroxy- (preparation of) 2085-71-6 CAPLUS
2-Naphthaleneacetamide, 4-cyclopropyl-1-hydroxy- (7CI, 8CI) (CA INDEX NAME) DOCUMENT TYPE:

L4 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1964:52602 CAPLUS
DOCUMENT NUMBER: 60:52602
ORIGINAL REFRERENCE NO: 50:52602
PATENT ASSIGNEK (S): 12-Alkylamino-1-(2-naphthyl)ethanols
SOURCE: 13 pp.
Patent
LANGUAGE: Patent
Unavailable ORIGINAL REFERENCE | TITLE: PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: PATENT INFORMATION:

PATENT NO. KIND DATE BE APPLICATION NO. DATE BE 624532 19630507 BE
GB 1005024 GB
PRIORITY APPLM. INFO.: GB
19611108
GI For diagram(s), see printed CA Issue.
AB 2-Naphthylglyoxal hydrate (I) is mixed with amines and hydrogenated to give II which can be used to treat coronary arterial disorders. A solv of 4 parts 2-C10H7COCH2Br in 30 parts Me250 is kept 48 hrs. at room temmerature

A solution

temperature
to give I, m. 110° (H2O). A mixture of 0.5 part PtO2 and 15 parts
EtOH is egitated at room temperature under H until H absorption stops, 15

iso-PrNH2 and 2 parts I are added, and the mixture is soitated at room

iso-PrNH2 and 2 parts I are added, and the mixture is agitated at room temperature under H until H absorption stops to give 2-isopropylamino-1-{2-naphthyl}ethanol, m. 105-6°. Similarly prepared are the following II (R. m.p. and m.p. HCl salt givan): sec-Bu, 82-3° (patr. ether), --, iso-Bu, --, 196-8° (MeOHe2CO), Pr. 98-9°, 192-3° (MeOH-ETOAC), tert-Bu, 129-30°, --, Et, 110-11°, --, Bu, 94, --. Also prepared are 2-isopropylamino-1-(1-methoxy-2-naphthyl) ethanol, m. 140-2°, 1-(2-naphthyl)-2-isopropylamino-1-(1-methoxy-2-naphthyl) ethanol, m. 177-8° (MeOH-ETOAC), and 1-methoxy-2-naphthylglyoxal hydrate, m. 110° (aqueous ETOH).

IT 93025-08-2, 2-Naphthalenemethanol, a-(isopropylamino)methyl-1-methoxy-(preparation of)

RN 93025-08-2 CAPIUS

C 2-Naphthalenemethanol, a-{(isopropylamino)methyl]-1-methoxy-(7CI) (CA INDEX NAME)

L4 ANSWER 52 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1953:454730 CAPLUS

ORIGINAL REFERENCE NO.: 59:99466-h,9947a-g

ORIGINAL REFERENCE NO.: 59:99466-h,9947a-g

Synthesis of furano compounds. XXV. Unequivocal synthesis of furano compounds. XXV. Unequivocal synthesis of furano compounds. XXV. Unequivocal synthesis of several naphthofurans

AUTHON(S): Synthesis of furano compounds. XXV. Unequivocal cynthesis of several naphthofurans

CORPORATE SOURCE: Synthesis of furano compounds. XXV. Unequivocal cynthesis of several naphthofurans

CORPORATE SOURCE: Universal cynthesis of several naphthofurans

DOCUMENT TYPE: Journal Document

DOCUMENT TYPE: Journal (a-dinaphthylene oxide)

I For diagram(s), see printed CA Issue.

AB Dinaphthof(1',2':2,3:2'',1'':4,5] furan (a-dinaphthylene oxide) (I) and dinaphthof(2',1':2,3:1'',2'':4,5] furan (a-dinaphthylene oxide) (I) and dinaphthof(2',1':2,3:1'',2'':4,5] furan (a-dinaphthylene oxide) (I) and inaphthof(2',1':2,3:1'',2'':4,5] furan (a-dinaphthylene oxide) (I) extremely an inaphthylene oxide) (I) yellow oxides (I) yellow needles, m. 170-80' yellow needles, m. 126-7' (EXCH). 1,2-MeoClOH6COM (6.7 g.) and 3 cc. CC. COC12, refluxed 2 h. with 1 drop CSHSN and evaporated again with CGH6, dissolved in 30 cc. dvy CGH6, added dropwise with cooling during 1 h. tc. CKM2 from 14.0 g. HENCON (NO) Me in 150 cc. Et2O, and refrigerated overnight, and the resulting brown, oily diszoketone (III) treated with Acoh yielded (a,7-benco-3-coumarone (IV), needles, m. 115-17' (EXCH). III in 90 cc. dioxane added dropwise during 1 h. at 70 80' to 80 cc. 404 AgNO3 in NH40H, heated 3 h. on the water bath, filtered, and diluted with H2O precipitated the anide (V) of 1,2-MeoCOH6COCOCK (VI), needles, m. 171-3' (EXCH). VI (1.0 g.), 8.0 architched vielded VI, plates, m. 171-3' (EXCH). VI (1.0 g.), 8.0 architched vielded VI, plates, m. 171-3' (EXCH). VI (1.0 g.), 8.0

and acidified yielded VI, plates, m. 171-3° (RtOH). VI (1.0 g.), 8.0 cc. AcOH, and 8 cc. MBr refluxed 4-5 h. and poured onto crushed ice gave 1-hydroxy naphthalene-2-acetic acid lactone (VII), plates, m. 108-9° (ECOH). VII (1.0 g.), 5.0 g. BzZO, and 1.0 g. dry NaOBz heated 3 h. at 170-80° under COZ and then 0.5 h. on the water bath with equeous XZCO3, the solution decanted, the residue again heated with

aqueous KZCO3, and the combined alkaline aqueous solns. acidified with HCl and

X2CO3, and the combined alkaline aqueous soins, acidited with HLI and ered yielded 0.15 g. 3-benzoyl-6,7-benzocoumaran-2-one (VIII), light green needles, m. 136-8° (EtOH); yellow-green in concentrated H2SO4; the alkali-insol. residue recrystd. from AcOH yielded 0.5 g. enol benzoate of VIII. VIII (0.15 g.), 10 cc. AcOH, and 4.0 g. HBr refluxed 6 h. and poured into H2O yielded 2-phenyl-6,7-benzocoumarone (IX), m. 88-90° (EKOH). IX (4.0 g.), 2.0 g. HCONMe2, and 3.0 cc. POCI3 heated 6-7 h. on the water bath yielded 4.2 g. 3-CHO derivative (X) of IX, needles, m. 136-7° (EtOH or AcOH); 2.4-dinitrophenylhydrazone, red, m. above 300° (PNO2). X reduced by the Wolff-Kishner procedure gave the 3-Me derivative of IX, needles, m. 118-19° (EtOH). X (4.2 g.), 3.0 g. hippuric acid, 1.5 g. NaOAc, and 10.0 cc. Ac2O heated 15-20 min. on the water bath and treated with EtOH yielded the azolactone, yellow needles, m. 219-20° (CGH6); a 4.0-g. portion and 80 cc. 10% aqueous alc. KOH refluxed 6-8 h. gave the brown, tacky 3-CH2COCOZH derivative (XI) of IX. Crude XI (1.0 g.) in 10.0 cc. AcOH refluxed 4-5 h. with 5.0 cc. HBr, and

ANSWER 52 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) cc. abs. NeOR, treated with 1.0 g. BcCHZBr, refluxed 2 h., ccoled, refrigerated overnight, filtered, and concd. yielded He ester (XXII) of 2-benzoyl-4,5-benzocoumarone-3-carboxylic acid (XXIII), m. 90°.

XXII sapond. with aq. alc. 10t NaOR, acidified, and extd. with Et20 yielded XXIII m. 184°, deep purple in concol. HZS04. XXIII refluxed 0.5 h. with SCC12, evapd., dissolved in CS2, treated with 1.0 g. AlCl3, and cooled 6 h., the CS2 decanted, the residue treated with HZO, and the crude product chromatographed on Al2O3 yielded 1'', 4''-dioxo-1'', 4''-dihydrodinaphtho [2', 1': 2, 3: 2'', 3'': 4, 5] furan, m. 270-1' (C6H6). 6, 7-Isomer of XXI (0.8 g.) added to 1.0 g. Na in 10 cc. abs. NeOR, treated with 0.7 g. BcCHZBP, refluxed 4 h., refrigerated, sapond. with aq. NaOH, and acidified yielded 2-benzoyl-6,7-benzocoumarone-3-carboxylic acid (XXIV), m. 182-5' (AcoH). XXIV in CS2 refluxed with SOC12 and evapd., the residue in CS2 treated several hrs. with cooling with 0.5 g. AlCl3, the CS2 decanted, the residue decompd. with HZO, and the product chromatographed yielded 1', 4'-dioxo-1' (A-diiyyodinaphtho[2', 3': 2, 3: 2'', 1'': 4, 5) furan, m. 225-8' (AcOH).

(ACOR): 92028-75-6, 2-Naphthaleneacetamide, 1-methoxy-(preparation of) 92028-75-6 CAPLUS 2-Naphthaleneacetamide, 1-methoxy- (7CI) (CA INDEX NAME)

ANSWER 52 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) the resulting gummy mass mixed with CaO and distd. gave I, needles, m. 180-1* (chromatographed and recrystd. from CGH6-ELOH and CGH6); 2.4.7-trinitrofluorenone adduct, gray plates, m. 269-71* (ACCH). 2-C10H7OCH2Bz (12.0 g.) in 250 cc. CGH6 refluxed 18 h. with 72.0 g. P205 yielded 1003 3-phenyl-4,5-benzocumarone (XII), brown, green-fluorescing liq., bz 200°, orange-red picrate m. 105°. 2-C10H7OMG (31.6 g.) in 50 cc. dry C52 treated with 28.0 g. BzCl and then with shaking and cooling with 27.0 g. powd. AlCl3, kept overnight, and evapd., and the residue decompd. with icad B20, acidified with HCl, and blown with steam yielded 17.0 g. 1,2-BzClOHGOH (XII), yellow plates, m. 135-7* (SLOH). XIII (5.0 g.), 5.0 cc. BCHZCOZER, 12.0 g. XECJ33 and 40.0 cc. dry Ma2CO refluxed 6-8 h. and worked up yielded 7.0 g. cilly Rt ester of 1,2-BzClOHGOCHECOZH (XIII) which refluxed 0.5 h. with 40 cc. 108 aq.-alc. NaCH, concd., and acidified gave 3.5 g. XIII, m. 174° (CGH6). XIII (3.5 g.), 28.0 cc. Ac2O, and 6.0 g. NaOac refluxed 0.5 h. poured into H2O, and extd. with E2O yielded 2.1 g. viocous XIII orange-red picrate m. 105°. XII (2.9 g.) in 1.0 g. HCONNe2 treated dropwise with cooling with 1.4 cc. POCI3, heated 2 h. on the vater bath, cooled, treated with aq. Na2CO3, and filtered yielded 1.7 g. 2-CHO deriv. (XIV) of XII, plates, m. 121-2° (ECCH); 2, 4-dinitrophenylhydrazone, red needles, m. 281-2° (CGH6); and 15° x XII, plates, m. 121-2° (ECCH); 2, 24-dinitrophenylhydrazone, red needles, m. 281-2° (CGH6); and 15° x XII with 50.2 g.) red to the form the BzOH, bolled with concd. HCl, and cooled gave the 2-CH2COCOZH deriv. (XV) of XII, leaflets, m. 214° with H2O, satd. with SO2, filtered from the BzOH, bolled with concd. HCl, and cooled gave the 2-CH2COCOZH deriv. (XV) of XII, leaflets, m. 214° with sintering at 190° (decompn.), dark red in concd. H2SO4. Crude XV (0.05 g.), 2.0 cc. AcOH, and 1 cc. 48% HBr refluxed 3 h. and poured into H2O gave the 4'-COZH deriv. (XV) of XII, hal

L4 ANSWER 53 OF 55
ACCESSION NUMBER:
DGCUMENT NUMBER:
ORIGINAL REFERENCE NO:
S8:5997f-h,5598a-b
TITLE:
Naphthalene derivatives
Stephenson, John S.
PATENT ASSIGNEE(S):
S0URCE:
S8 DD. 8 pp. Patent Unavailable SOURCE: DOCUMENT TYPE: LANGUAGE: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE GB 909357 US 3215732 19621031 1965 GB US 19600504

US 3215732 1965 US
For diagram(s), see printed CA Issue.
I, where Rl is H or Me, R2 a branched-chain Pr or Bu, and where the nucleus may, optionally, bear l or more halo substituents and (or) l or more alkyl or alkows substituents of not more than 4 C atoms, and the nontoxic, acid-addition salts, could be synthesized. Thus, a solution of 2-naphthanyl bromide 10 in HeOH 180 was stirred and NaEMM 3 parts added quickly, below 25 the mixture stirred for 30 min., and then poured onto ice and extracted with EtO. The extract was washed with HZO, dried (Na2SO2), and evaporated to dryness, the residue dissolved in anhydrous 90

and refluxed with iso-PrNH2 20 parts 16 h. The solution was then

evaporated to
dryness in vacuo and the solid residue suspended in H2O 50, acidified with
HBr, and allowed to crystallize, and the product recrystd. from aqueous

L4 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

● HC1

14 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1962:475840 CAPLUS

DOCUMENT NUMBER: 57:75840

GRIGHAL REFERENCE NO.: 57:15063a-c

TITLE: Dehydrobromination of dibromides of isomeric beneate trabydrocounarins

AUTHOR(5): Shusherine, N. P., Dmitrieva, N. D.; Levina, R. Ya. CORPORATE SOURCE: Shusherine, N. P., Dmitrieva, N. D.; Levina, R. Ya. CORPORATE SOURCE: CODEN: ZONEMA; ISSN: 0044-460X

DOCUMENT TYPE: Unavailable

AB cf. Ca 52, 6330e; S4, 12127a; 57, 13716h. 7,8-Benzo-A9, 10
tetrahydrocoumarin and Br in cold Et20 gave 9, 10-dibromo-7,8benzohexahydrocoumarin, which heated until all Her evolution ceased gave a distillate, bi3 210-15', which leached with aqueous NaOH left a residue of 7,8-benzo-3,4-dihydrocoumarin, an.

74-5', did not react with maleic anhydride, but gave the corresponding piperidide, m. 161-2', and anide, m. 106-7', after treatment with the bases in aqueous medium. Bromination of 5,6-benzo-3,0-dihydrocoumarin, as above in CCl4 gave the 9,10-dibronide, m. 78-80', which heated in dry air gave mixed products, bi3 220-5', which could not be separated satisfactorily. However treatment with maleic anhydride gave 6t maleic anhydride adduct of 5,6-benzo-3,6-dihydrocoumarin, decomposed at 333-4' (with aqueous NaOH this gave the tetrabasic acid, which with CEZNZ gave tetrahe ester, m. 205-6'). Treatment of the mixed products with piperidine gave 3-(2-hydroxy-1-naphthyl)propiopiperidide, m. 128-9'. Similarly was prepared the amide, m. 170', indicating the original presence of 5,6-benzo-3,4-dihydrocoumarin in the dehydrobrominated mixture (preparation of)
N 2028-78-9 CAPLUS
CN 2-Naphthalenepropionamide, 1-hydroxy- (7CI) (CA INDEX NAME)

L4 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1954:68114 CAPLUS
OCCIMENT NUMBER: 48:68114 CAPLUS
1954:68114 CAPLUS
48:68114 CAPLUS
48: CÓDEN: JOCEAN, ISSN: 0022-3263

MENT TYPE: Journal

UAGE: Unavailable:

2.5-(MeO)2C6H3CH2CH:CH2 heated with KOH in (CH2OH)2 at 170-5° gives

85% 2.5-dimethoxy-1-propenylbenzene (I), b13 126°, n20D 1.556.

Adding (20 ain.) 10 cc. 4N H2SO4 to 1 g. I in 10 cc. ether and 21 g. NaNO2

in 8 cc. H2O gives 18 g. (from 20 runs) 2,5-dimethoxy-1-propenylbenzene

pseudonitrosite (II), m. 130° (decomposition). Adding 2 cc. Ac20 containing

1 drop concentrated H2SO4 to 7 g. II in 20 cc. Ac20 cooled with ice, and DOCUMENT TYPE: LANGUAGE: OTHER SOURCE(S): pseudonitrosite (II), m. 130° (decomposition). Adding 2 cc. Ac20 containing 1 drop concentrated H2SO4 to 7 g. II in 20 cc. Ac20 cooled with ice, and after 2.

Idrop concentrated H2SO4 to 7 g. III in 20 cc. Ac20 cooled with ice, and after 2.

A, pouring it into H2O give 2,5-(MeO)2C6H3CH(OH)CH(NO2)Me (III), decomposing it into H2O give 2,5-(MeO)2C6H3CH(OH)CH(NO2)Me (III), on distillation Reducing 7 g. III in 100 cc. EtOH, 50 cc. AcOH, and 3 cc. concentrated HCl at a Hg cathode below 60°, neutralizing the solution with NaOAc, evaporating it in vacuo to dryness, dissolving the residue in 50 cc. H2O, and saturating it with NaHCO3 give 3.1 g.

2,5-(MeO)2C6H3CH(OH)CH(NHC)He
(IV), an 156°, which, acetylated with Ac20 and C5H5N, gives the C-Ac derivative m. 98-100°. Refluxing 1 g. IV in 10 cc. PhMe with 3 cc. PCO13, 75 min., pouring the mixture into ice H2O, making it alkaline, extracting
with ether, and passing the residue of the ether extract in C6H6 through A12O3 give 0.65 g. 1,3-dimethoxy-5,8-dimethoxy-quinoline (IVA) pale yellow needles, m. 70° HCl salt, deep yellow crystals, m. 234°, pierolonate, m. 230°). Heating 25 g. 2,5-(MeO)2C6H3CH0, 20 g. EtCHO, and 15 g. fused EtCO2Na 48 h. at 140-50°, then heating the melt with 300 cc. 4N NaOH to bolling, washing with C6H6, and neutralizing the agueous solution give 20 g. 2,5-(MeO)2C6H3CHCMCO2H, m. 111°, gives ultimated by 10 g. 2,5-(MeO)2C6H3CHCMCHCHNE), b3 140°, whose HCl salt, m. 118°, and Ac derivative (V), m. 111°, Cyclization of i g. V with PCCl3 gives 0.6 g. oily 1,3-dimethyl-5,8-dimethoxy-3,4-dihydroisoquinoline (VI) (HCl salt m. 177° picrolonate, m. 185-6°). Refluxing 0.5 g. VI in 10 cc. Decalin with 50 mg. 58 Pd-C in a CO2 atmospheric 8 h., extracting the filtered solution with 4N HCl, and making the washed (ether) acid solution alkaline give 0.4 g. IVA. Passing dry HCl into 13 g. 2,5-(MeO)2C6H3COEt in 100 cc. ether and 9 g. BuNO2 and keeping the mixture overnight give 2 g. 2,5-(MeO)2C6H3COC(HNOX)He, m. 116°, and, from the mother liquor, 5.48 g. of a stereoisomer Page 32 saeed

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 272.60 434.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

CA SUBSCRIBER PRICE ENTRY SESSION -40.15 -40.15

STN INTERNATIONAL LOGOFF AT 21:50:12 ON 03 APR 2005